CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10725409,107254093,3,F,,20211217,20150121,20211229,EXP,,CA-ROCHE-1522668,ROCHE,"Reporter known to Health Authority, Harris M, Larsen G, Montaner JSG Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22(14):1890-2.",44,YR,,M,Y,,,20211229,,MD,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,107254093,HO,,,107254093,11,,,355,DAY,107254093,1,Depression
11844743,118447432,2,F,20150101,20151214,20151217,20211118,EXP,,RU-VIIV HEALTHCARE LIMITED-RU2015GSK177983,VIIV,,,,,F,Y,,,20211118,,CN,RU,RU,EFAVIRENZ,Apathy;Dizziness;Memory impairment;Pyrexia;Seizure;Vomiting,118447432,OT,,,118447432,1,201511,,,,118447432,1,HIV infection
11846834,118468342,2,F,20150101,20151214,20151217,20211118,EXP,,RU-GLAXOSMITHKLINE-RU2015GSK177983,GLAXOSMITHKLINE,,,,,F,Y,,,20211118,,CN,RU,RU,EFAVIRENZ,Apathy;Dizziness;Memory impairment;Pyrexia;Seizure;Vomiting,118468342,OT,,,118468342,1,201511,,,,118468342,1,HIV infection
12237989,122379893,3,F,,20160331,20160405,20211119,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016GSK044584,VIIV,,,,,F,Y,,,20211119,,CN,GB,GB,SUSTIVA,Death,122379893,OT,,,,,,,,,122379893,1,Product used for unknown indication
12238174,122381743,3,F,,20160331,20160405,20211119,EXP,,GB-GLAXOSMITHKLINE-GB2016GSK044584,GLAXOSMITHKLINE,,,,,F,Y,,,20211119,,CN,GB,GB,SUSTIVA,Death,122381743,DE,,,,,,,,,122381743,1,Product used for unknown indication
12810571,128105713,3,F,,20211209,20161005,20211221,EXP,,CA-APOTEX-2016AP012493,APOTEX,,,,,M,Y,,,20211221,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,128105713,OT,,,,,,,,,128105713,1,Product used for unknown indication
14301231,143012314,4,F,,20211019,20171219,20211027,EXP,,CA-APOTEX-2017AP022577,APOTEX,,,,,M,Y,,,20211027,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,143012314,DE,,,,,,,,,143012314,1,Product used for unknown indication
14957287,149572872,2,F,,20211001,20180531,20211006,EXP,,CA-APOTEX-2018AP014010,APOTEX,,46,YR,,M,Y,72,KG,20211006,,HP,CA,CA,EFAVIRENZ,Drug interaction;Hepatotoxicity;Transaminases increased,149572872,OT,,,,,,,,,149572872,1,Pulmonary tuberculosis
15245128,152451282,2,F,20180209,20180731,20180806,20211119,EXP,,LS-GLAXOSMITHKLINE-LS2018GSK140125,GLAXOSMITHKLINE,,26,YR,,M,Y,45,KG,20211119,,MD,LS,LS,EFAVIRENZ,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tremor;Vomiting,152451282,DE,,,152451282,1,20180216,20180715,153,DAY,152451282,1,HIV infection
15246169,152461692,2,F,20180209,20180731,20180806,20211119,EXP,,LS-VIIV HEALTHCARE LIMITED-LS2018GSK140125,VIIV,,26,YR,,M,Y,45,KG,20211119,,MD,LS,LS,EFAVIRENZ,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tremor;Vomiting,152461692,DE,,,152461692,1,20180216,20180715,153,DAY,152461692,1,HIV infection
15348259,153482592,2,F,,20180830,20180904,20211118,EXP,FR-AFSSAPS-ST20181160,FR-GLAXOSMITHKLINE-FR2018158242,GLAXOSMITHKLINE,,40,YR,,M,Y,,,20211118,,MD,FR,FR,SUSTIVA,Lipodystrophy acquired,153482592,OT,,,153482592,1,19990412,20050512,2222,DAY,153482592,1,HIV infection
15348740,153487402,2,F,,20180830,20180904,20211118,EXP,FR-AFSSAPS-ST20181160,FR-VIIV HEALTHCARE LIMITED-FR2018158242,VIIV,,40,YR,,M,Y,,,20211118,,MD,FR,FR,SUSTIVA,Lipodystrophy acquired,153487402,OT,,,153487402,1,19990412,20050512,2222,DAY,153487402,1,HIV infection
15473109,154731099,9,F,,20211216,20181008,20211224,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-092264,BRISTOL MYERS SQUIBB,,29,YR,,M,Y,,,20211224,,HP,PT,PT,EFAVIRENZ,Drug-induced liver injury;Hepatic fibrosis,154731099,LT,,,,,,,,,154731099,1,Chronic hepatitis C
15626564,156265642,2,F,20040806,20160713,20181116,20211118,EXP,,JP-GLAXOSMITHKLINE-JP2016GSK200647,GLAXOSMITHKLINE,,46,YR,,M,Y,,,20211118,,MD,JP,JP,EFAVIRENZ,Diabetes mellitus;Hepatic function abnormal;Hypercholesterolaemia;Hypertriglyceridaemia;Lipoatrophy,156265642,OT,,,156265642,1,20050716,20090828,1460,DAY,156265642,1,HIV infection
15626573,156265732,2,F,20040806,20160713,20181116,20211118,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2016GSK200647,VIIV,,46,YR,,M,Y,,,20211118,,MD,JP,JP,EFAVIRENZ,Diabetes mellitus;Hepatic function abnormal;Hypercholesterolaemia;Hypertriglyceridaemia;Lipoatrophy,156265732,OT,,,156265732,1,20050716,20090828,1460,DAY,156265732,1,HIV infection
15681335,156813352,2,F,,20211004,20181203,20211008,EXP,,CA-ABBVIE-18S-028-2576421-00,ABBVIE,,,,,M,Y,,,20211008,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,156813352,OT,,,,,,,,,156813352,1,Product used for unknown indication
15902280,159022804,4,F,20160101,20211014,20190201,20211028,EXP,,US-GILEAD-2019-0387827,GILEAD,,47,YR,A,M,Y,72.56,KG,20211028,,LW,US,US,SUSTIVA,Abnormal dreams;Anhedonia;Anxiety;Blood creatinine increased;Economic problem;Emotional distress;Fatigue;Pain;Protein urine present;Quality of life decreased;Renal failure;Renal impairment;Renal injury,159022804,OT,,,159022804,1,200805,2015,464,DAY,159022804,1,HIV infection
15920383,159203834,4,F,,20211004,20190205,20211014,EXP,,CA-TEVA-2019-CA-1007031,TEVA,,52,YR,A,M,Y,,,20211014,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,159203834,OT,,,,,,,,,159203834,1,HIV infection
16052306,160523063,3,F,,20190514,20190308,20211118,EXP,,US-GLAXOSMITHKLINE-US2019040980,GLAXOSMITHKLINE,,,,,M,Y,,,20211118,,HP,US,US,SUSTIVA,Drug resistance,160523063,OT,,,,,,,,,160523063,1,HIV infection
16052308,160523083,3,F,,20190514,20190308,20211118,EXP,,US-VIIV HEALTHCARE LIMITED-US2019040980,VIIV,,,,,M,Y,,,20211118,,HP,US,US,SUSTIVA,Drug resistance,160523083,OT,,,,,,,,,160523083,1,HIV infection
16080755,160807556,6,F,,20211028,20190316,20211111,EXP,,CA-AUROBINDO-AUR-APL-2019-013379,AUROBINDO,,44,YR,,M,Y,,,20211111,,HP,CA,CA,SUSTIVA,Anxiety,160807556,HO,,,,,,,,,160807556,1,Psychotic disorder
16081155,160811558,8,F,,20211013,20190316,20211028,EXP,,CA-AUROBINDO-AUR-APL-2019-013363,AUROBINDO,,54,YR,,M,Y,,,20211028,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,160811558,HO,,,,,,,,,160811558,1,HIV infection
16170692,161706924,4,F,,20211018,20190408,20211025,EXP,,AT-MYLANLABS-2019M1031449,MYLAN,"Taylor N, Touzeau V, Geit M, Gisinger M, Egle A, Greil R, et al... Raltegravir in Pregnancy: A Case Series Presentation.. International Journal of STD + AIDS.. 2011;22(6):358 -60",39,YR,,F,Y,,,20211025,,HP,AT,AT,EFAVIRENZ,Acute stress disorder;Drug abuse;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,161706924,HO,,,161706924,21,,,17,DAY,161706924,1,Antiretroviral therapy
16277931,162779317,7,F,20160601,20211011,20190506,20211015,EXP,,US-GILEAD-2019-0405253,GILEAD,,32,YR,A,F,Y,81.65,KG,20211015,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Gait disturbance;Oedema peripheral;Pain;Renal failure;Tooth loss;Tubulointerstitial nephritis,162779317,HO,,,162779317,1,2011,201603,1703,DAY,162779317,1,HIV infection
16340534,163405344,4,F,,20211028,20190522,20211110,EXP,,CA-AUROBINDO-AUR-APL-2019-027585,AUROBINDO,,54,YR,,M,Y,,,20211110,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,163405344,OT,,,,,,,,,163405344,1,HIV infection
16340539,163405394,4,F,,20211028,20190522,20211111,EXP,,CA-AUROBINDO-AUR-APL-2019-027542,AUROBINDO,,44,YR,,M,Y,,,20211111,,HP,CA,CA,SUSTIVA,Anxiety,163405394,OT,,,,,,,,,163405394,1,Psychotic disorder
16346235,163462354,4,F,,20211216,20190523,20211228,EXP,,CA-AUROBINDO-AUR-APL-2019-027597,AUROBINDO,,54,YR,,M,Y,,,20211229,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,163462354,OT,,,,,,,,,163462354,1,HIV infection
16438510,164385104,4,F,,20211220,20190617,20211227,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK106137,VIIV,,,,,M,Y,,,20211227,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,164385104,HO,,,,,,,,,164385104,1,Product used for unknown indication
16438515,164385154,4,F,,20211220,20190617,20211227,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK106137,GLAXOSMITHKLINE,,,,,M,Y,,,20211227,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,164385154,OT,,,,,,,,,164385154,1,Product used for unknown indication
16507810,165078102,2,F,20020101,20190624,20190701,20211118,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2019GSK116835,VIIV,,,,E,M,Y,,,20211118,,MD,DE,DE,EFAVIRENZ;SUSTIVA,Aortic stenosis;Arthralgia;Asthenia;Bronchial carcinoma;Chest pain;Coronary artery disease;Dysphagia;Dyspnoea;Haematuria;Myopathy;Papillary renal cell carcinoma;Stenosis;Systemic scleroderma;Weight decreased,165078102,HO,,,165078102,1,199702,201510,,,165078102,1,HIV infection
16507857,165078572,2,F,20020101,20190624,20190701,20211118,EXP,,DE-GLAXOSMITHKLINE-DE2019GSK116835,GLAXOSMITHKLINE,,,,E,M,Y,,,20211118,,MD,DE,DE,EFAVIRENZ;SUSTIVA,Aortic stenosis;Arthralgia;Asthenia;Bronchial carcinoma;Chest pain;Coronary artery disease;Dysphagia;Dyspnoea;Haematuria;Myopathy;Papillary renal cell carcinoma;Stenosis;Systemic scleroderma;Weight decreased,165078572,OT,,,165078572,1,199702,201510,,,165078572,1,HIV infection
16543052,165430524,4,F,,20211020,20190709,20211028,EXP,,CA-AUROBINDO-AUR-APL-2019-037770,AUROBINDO,,,,,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,165430524,OT,,,,,,,,,165430524,1,Product used for unknown indication
16653423,166534236,6,F,20130101,20211011,20190731,20211105,EXP,,US-GILEAD-2019-0420315,GILEAD,,,,A,M,Y,89.796,KG,20211105,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Bone loss;Depression;Economic problem;Emotional distress;Mobility decreased;Multiple fractures;Osteonecrosis;Pain;Patella fracture;Tooth loss,166534236,OT,,,166534236,1,20080715,20190215,127,MON,166534236,1,HIV infection
16678638,166786386,6,F,20150101,20211130,20190807,20211209,EXP,,US-GILEAD-2019-0421720,GILEAD,,59,YR,A,F,Y,63.5,KG,20211209,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,166786386,HO,,,166786386,1,20100506,20160606,73,MON,166786386,1,HIV infection
16734610,167346103,3,F,,20211020,20190823,20211029,EXP,,CA-AUROBINDO-AUR-APL-2019-054681,AUROBINDO,,,,,M,Y,,,20211029,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,167346103,DE,,,,,,,,,167346103,1,Product used for unknown indication
16853159,168531596,6,F,20040801,20210509,20190925,20211020,EXP,,US-GILEAD-2019-0429655,GILEAD,,66,YR,E,M,Y,58.96,KG,20211020,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood cholesterol increased;Blood creatinine increased;Bone density decreased;Economic problem;Emotional distress;Fall;Fear;Foot fracture;Lipids increased;Loss of personal independence in daily activities;Lower limb fracture;Multiple fractures;Muscle spasms;Muscular weakness;Osteopenia;Osteoporosis;Pain;Quality of life decreased;Renal impairment;Rib fracture;Spinal cord compression;Upper limb fracture,168531596,OT,,,168531596,1,20041115,20080926,1411,DAY,168531596,1,HIV infection
16854746,168547462,2,F,20120611,20211214,20190926,20211229,EXP,,US-GILEAD-2019-0429522,GILEAD,,52,YR,A,F,Y,69.841,KG,20211229,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Nephrogenic anaemia;Pain;Quality of life decreased;Renal failure,168547462,OT,,,168547462,1,201107,20130812,,,168547462,1,HIV infection
16856454,168564543,3,F,20120101,20211020,20190926,20211103,EXP,,US-GILEAD-2019-0429624,GILEAD,,23,YR,A,M,Y,72.562,KG,20211103,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Death;Decreased activity;Emotional distress;Fear;Impaired work ability;Loss of personal independence in daily activities;Pain;Quality of life decreased;Renal failure;Renal injury;Skeletal injury,168564543,OT,,,168564543,1,2008,2013,1080,DAY,168564543,1,HIV infection
16860051,168600514,4,F,20140301,20211115,20190927,20211130,EXP,,US-GILEAD-2019-0429732,GILEAD,,59,YR,A,M,Y,77,KG,20211130,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Decreased activity;Economic problem;Emotional distress;Osteoporosis;Quality of life decreased,168600514,OT,,,168600514,1,20100826,20140605,1379,DAY,168600514,1,HIV infection
16863190,168631903,3,F,20130101,20211027,20190927,20211111,EXP,,US-GILEAD-2019-0429518,GILEAD,,57,YR,A,M,Y,,,20211111,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia;Anhedonia;Anxiety;Chronic kidney disease;Decreased activity;Depression;Economic problem;Emotional distress;Fatigue;Fear;Hypercalcaemia;Hyperparathyroidism;Loss of personal independence in daily activities;Mobility decreased;Pain;Quality of life decreased,168631903,HO,,,168631903,1,20131118,20160510,904,DAY,168631903,1,HIV infection
16934410,169344102,2,F,20190901,20191014,20191018,20211202,EXP,,NVSC2019BR005027,NOVARTIS,,62,YR,,F,Y,,,20211202,,CN,BR,BR,EFAVIRENZ,Dizziness;Intraocular pressure decreased;Malaise;Pruritus;Transplant rejection;Vision blurred,169344102,OT,,,169344102,1,2006,,,,169344102,1,Product used for unknown indication
17075956,170759564,4,F,20031224,20211007,20191126,20211015,EXP,,US-GILEAD-2019-0439500,GILEAD,,63,YR,A,M,Y,,,20211014,,LW,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Foot fracture;Hand fracture;Hip fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal failure;Rib fracture,170759564,OT,,,170759564,1,20020730,20050901,1129,DAY,170759564,1,HIV infection
17097939,170979395,5,F,20120101,20211109,20191202,20211124,EXP,,US-GILEAD-2019-0440104,GILEAD,,,,A,M,Y,,,20211124,,LW,US,US,SUSTIVA,Arthralgia;Bone density abnormal;Bone density decreased;Bone loss;Hip arthroplasty;Joint arthroplasty;Multiple fractures;Osteonecrosis;Osteoporosis;Tooth fracture;Tooth loss,170979395,OT,,,170979395,1,2008,2008,,,170979395,1,HIV infection
17110907,171109074,4,F,20150101,20211017,20191204,20211028,EXP,,US-GILEAD-2019-0440237,GILEAD,,,,A,F,Y,,,20211028,,LW,US,US,SUSTIVA,Back disorder;Bone density decreased;Bone loss;Intervertebral disc degeneration;Multiple fractures;Osteonecrosis;Osteoporosis;Tooth loss;Upper limb fracture,171109074,OT,,,171109074,1,2005,200612,,,171109074,1,HIV infection
17220278,172202786,6,F,20160101,20211011,20191231,20211019,EXP,,US-GILEAD-2019-0444912,GILEAD,,39,YR,A,M,Y,108.84,KG,20211019,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;End stage renal disease;Fatigue;Pain;Renal disorder;Renal failure;Spinal osteoarthritis,172202786,OT,,,172202786,1,2001,202007,,,172202786,1,HIV infection
17223371,172233712,2,F,,20211217,20200102,20211229,EXP,,CA-ROCHE-2504137,ROCHE,,44,YR,,M,Y,,,20211229,,HP,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,172233712,HO,,,,,,,,,172233712,1,Depression
17244373,172443736,6,F,20151129,20211011,20200107,20211025,EXP,,US-GILEAD-2020-0445052,GILEAD,,50,YR,A,M,Y,64.86,KG,20211025,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Hip fracture;Multiple fractures;Nephrolithiasis;Osteoporosis;Pain,172443736,OT,,,172443736,1,201208,201610,1225,DAY,172443736,1,HIV infection
17244469,172444696,6,F,20150612,20211022,20200107,20211105,EXP,,US-GILEAD-2020-0445093,GILEAD,,69,YR,E,M,Y,117.93,KG,20211105,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Mobility decreased;Pain;Proteinuria,172444696,OT,,,172444696,1,200808,20170714,3217,DAY,172444696,1,HIV infection
17244479,172444795,5,F,20100201,20211115,20200107,20211130,EXP,,US-GILEAD-2020-0445100,GILEAD,,41,YR,A,F,Y,,,20211130,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Death;Drooling;Economic problem;Emotional distress;End stage renal disease;Headache;Hypoaesthesia;Multiple fractures;Nausea;Pain;Pyelonephritis;Rash;Renal failure;Renal impairment;Sinusitis;Somnolence;Urinary tract infection;Vision blurred,172444795,HO,,,172444795,1,2004,2008,1106,DAY,172444795,1,HIV infection
17245635,172456356,6,F,20081203,20211019,20200108,20211028,PER,,US-GILEAD-2020-0445081,GILEAD,,49,YR,A,M,Y,86.17,KG,20211028,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Back pain;Bone density decreased;Economic problem;Emotional distress;Multiple fractures;Osteopenia;Osteoporosis;Pain;Rib fracture;Spinal compression fracture;Spinal fracture;Spinal operation;Therapeutic product effect decreased,172456356,OT,,,172456356,1,20130104,20130106,2,DAY,172456356,1,HIV infection
17412233,174122338,8,F,20150101,20211008,20200213,20211015,PER,,US-GILEAD-2020-0450638,GILEAD,,57,YR,A,M,Y,81.6,KG,20211015,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Economic problem;Emotional distress;Multiple fractures;Off label use;Osteopenia;Osteoporosis;Pain;Renal failure;Suicidal ideation,174122338,OT,,,174122338,1,201505,201508,,,174122338,1,HIV infection
17424136,174241365,5,F,20100506,20211115,20200217,20211129,EXP,,US-GILEAD-2020-0450654,GILEAD,,48,YR,A,M,Y,83.9,KG,20211129,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Economic problem;Emotional distress;Hip arthroplasty;Loss of personal independence in daily activities;Osteopenia;Pain;Renal failure,174241365,HO,,,174241365,1,20070109,200704,2115,DAY,174241365,1,HIV infection
17527872,175278725,5,F,,20211007,20200311,20211013,EXP,,US-GILEAD-2020-0454096,GILEAD,,,,A,M,Y,83.9,KG,20211013,,LW,US,US,SUSTIVA,Bone density decreased;Dysstasia;Economic problem;Emotional distress;Gait disturbance;Osteomalacia;Pain;Renal failure;Renal tubular injury;Vitamin D deficiency,175278725,OT,,,175278725,1,2002,2013,1198,DAY,175278725,1,HIV infection
17577715,175777155,5,F,20170101,20211208,20200324,20211224,EXP,,US-GILEAD-2020-0456092,GILEAD,,61,YR,A,M,Y,60.771,KG,20211223,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Dysstasia;Economic problem;Emotional distress;Fanconi syndrome acquired;Mobility decreased;Nephrogenic anaemia;Osteopenia;Osteoporosis;Pain;Renal impairment;Rib fracture,175777155,HO,,,175777155,1,2006,201709,,,175777155,1,HIV infection
17600360,1760036011,11,F,,20211223,20200330,20211229,EXP,,FR-MYLANLABS-2020M1032592,MYLAN,"Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, et al... Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects. An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11). PLoS Medicine. 2014;11(11):1-22",,,,F,Y,,,20211229,,MD,FR,FR,EFAVIRENZ,Cerebral ventricle dilatation;Foetal exposure during pregnancy;Pachygyria;White matter lesion,1760036011,CA,,,,,,,,,1760036011,1,HIV infection
17705704,177057043,3,F,20141026,20211018,20200424,20211021,EXP,,US-GILEAD-2020-0460888,GILEAD,,52,YR,A,M,Y,,,20211021,,LW,US,US,SUSTIVA,Chronic kidney disease;Nephrolithiasis;Renal failure;Skeletal injury,177057043,OT,,,177057043,1,2015,20160830,,,177057043,1,HIV infection
17714453,177144536,6,F,20040617,20211117,20200427,20211202,EXP,,US-GILEAD-2020-0460865,GILEAD,,33,YR,A,M,Y,73.016,KG,20211202,,LW,US,US,SUSTIVA,Acute kidney injury;Anxiety;Chronic kidney disease;Emotional distress;End stage renal disease;Hyperparathyroidism secondary;Mobility decreased;Pain;Renal cyst;Renal failure;Renal tubular necrosis,177144536,HO,,,177144536,1,20040112,20171023,5033,DAY,177144536,1,HIV infection
17742314,177423144,4,F,,20211001,20200505,20211008,EXP,,CA-ROCHE-2592280,ROCHE,,54,YR,,M,Y,,,20211008,,CN,CA,CA,SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,177423144,OT,,,,,,,,,177423144,1,HIV infection
17747940,177479406,6,F,20100101,20211013,20200505,20211208,EXP,,US-GILEAD-2020-0462872,GILEAD,,59,YR,A,F,Y,93.9,KG,20211208,,LW,US,US,SUSTIVA,Abdominal pain upper;Ankle fracture;Ankle impingement;Back pain;Bone density decreased;Bone marrow oedema;Chronic kidney disease;Emotional distress;Fall;Fibula fracture;Gait disturbance;Hypertension;Lower limb fracture;Mobility decreased;Multiple fractures;Osteoporosis;Pain;Posterior tibial tendon dysfunction;Tendonitis,177479406,HO,,,177479406,1,200601,201804,1823,DAY,177479406,1,HIV infection
17924422,179244225,5,F,20060101,20211115,20200622,20211130,EXP,,US-GILEAD-2020-0474191,GILEAD,,57,YR,A,M,Y,104.31,KG,20211130,,LW,US,US,SUSTIVA,Acute kidney injury;Anaemia of chronic disease;Anhedonia;Anxiety;Bone density decreased;Bone metabolism disorder;Chronic kidney disease;Dyspnoea;Emotional distress;End stage renal disease;Erectile dysfunction;Focal segmental glomerulosclerosis;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Pain;Proteinuria;Renal failure;Tooth loss,179244225,OT,,,179244225,1,2006,20120816,145,DAY,179244225,1,HIV infection
17924500,179245002,2,F,,20211025,20200622,20211105,EXP,,CA-ROCHE-2621283,ROCHE,,52,YR,,M,Y,,,20211105,,HP,CA,,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,179245002,OT,,,,,,,,,179245002,1,HIV infection
17930251,179302514,4,F,20150101,20211201,20200623,20211217,EXP,,US-GILEAD-2020-0474566,GILEAD,,61,YR,A,F,Y,47.166,KG,20211217,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;Foot fracture;Hip fracture;Multiple fractures;Osteopenia;Osteoporosis;Pain;Tooth loss,179302514,OT,,,179302514,1,20040101,20171231,5113,DAY,179302514,1,HIV infection
17936980,179369807,7,F,20121212,20211207,20200624,20211213,EXP,,US-GILEAD-2020-0475000,GILEAD,,52,YR,A,M,Y,93.424,KG,20211213,,LW,US,US,SUSTIVA,Acute kidney injury;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Emotional distress;End stage renal disease;Nephropathy;Pain;Renal failure;Somnolence,179369807,OT,,,179369807,1,2005,200903,5273,DAY,179369807,1,HIV infection
17945212,179452124,4,F,20100101,20211208,20200626,20211223,EXP,,US-GILEAD-2020-0475190,GILEAD,,,,A,M,Y,79.365,KG,20211223,,LW,US,US,EFAVIRENZ,Chronic kidney disease;Depression;Nephropathy;Renal failure;Renal injury;Renal mass;Skeletal injury;Tooth loss,179452124,OT,,,179452124,1,2001,200506,,,179452124,1,HIV infection
17945994,179459943,3,F,,20211228,20200626,20211231,EXP,E2B_02979508,CA-Accord-186584,ACCORD,,,,,M,Y,,,20211231,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,179459943,HO,,,,,,,,,179459943,1,Product used for unknown indication
17952409,179524094,4,F,20160101,20211203,20200626,20211221,EXP,,US-GILEAD-2020-0474171,GILEAD,,43,YR,A,F,Y,,,20211221,,LW,US,US,SUSTIVA,Chronic kidney disease;Gastrointestinal disorder;Pain;Renal failure;Renal injury;Skeletal injury,179524094,OT,,,179524094,1,201410,,,,179524094,1,HIV infection
17954859,179548593,3,F,,20211013,20200629,20211028,EXP,,CA-AUROBINDO-AUR-APL-2020-030609,AUROBINDO,,54,YR,,M,Y,,,20211028,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,179548593,OT,,,,,,,,,179548593,1,HIV infection
17973430,179734304,4,F,20140603,20211110,20200702,20211125,EXP,,US-GILEAD-2020-0478106,GILEAD,,52,YR,A,F,Y,,,20211125,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Fanconi syndrome acquired;Osteoporosis;Pain,179734304,OT,,,179734304,1,2003,2006,970,DAY,179734304,1,HIV infection
17982291,179822916,6,F,,20211204,20200706,20211217,EXP,,FR-AUROBINDO-AUR-APL-2020-032078,AUROBINDO,"Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, et al.. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the french perinatal cohort study (ANRS CO1/CO11).. PLOS Medicine. 2014;11(4)::1-22",,,,F,Y,,,20211217,,MD,FR,FR,EFAVIRENZ,Cerebral ventricle dilatation;Foetal exposure during pregnancy;Pachygyria;White matter lesion,179822916,OT,,,,,,,,,179822916,1,HIV infection
18021486,180214863,3,F,20140523,20211015,20200714,20211027,EXP,,US-GILEAD-2020-0482560,GILEAD,,59,YR,A,M,Y,,,20211027,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Multiple fractures;Osteonecrosis of jaw;Osteoporosis;Pain;Renal failure;Tooth fracture;Tooth loss,180214863,OT,,,180214863,1,20080602,20091102,17,MON,180214863,1,HIV infection
18026883,180268835,5,F,20150101,20211106,20200715,20211117,EXP,,US-GILEAD-2020-0479893,GILEAD,,,,E,F,Y,,,20211117,,LW,US,US,SUSTIVA,Bone density decreased;Chronic kidney disease;Emotional distress;End stage renal disease;Pain;Renal failure;Tooth loss,180268835,OT,,,180268835,1,2011,2015,,,180268835,1,HIV infection
18040288,180402883,3,F,20121101,20211208,20200717,20211223,EXP,,US-GILEAD-2020-0483314,GILEAD,,36,YR,A,M,Y,92.971,KG,20211223,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Decreased activity;Emotional distress;Fear;Insomnia;Loss of personal independence in daily activities;Pain;Quality of life decreased,180402883,OT,,,180402883,1,200604,20181126,,,180402883,1,HIV infection
18065589,180655893,3,F,,20211213,20200724,20211222,EXP,CA-MHPD-E2B_02992182,CA-Accord-191476,ACCORD,,44,YR,,M,Y,,,20211222,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,180655893,OT,,,180655893,13,,,365,DAY,180655893,1,Depression
18105559,181055594,4,F,20080101,20211106,20200804,20211119,EXP,,US-GILEAD-2020-0486479,GILEAD,,42,YR,A,M,Y,81.633,KG,20211119,,LW,US,US,SUSTIVA,Abdominal discomfort;Abnormal dreams;Anhedonia;Anxiety;Bone density decreased;Bone disorder;Bone loss;Decreased appetite;Emotional distress;Femur fracture;Hand fracture;Lower limb fracture;Multiple fractures;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal injury;Skeletal injury;Weight decreased,181055594,HO,,,181055594,1,2004,2017,1363,DAY,181055594,1,Hepatitis B
18114349,181143495,5,F,20120101,20211015,20200805,20211025,EXP,,US-GILEAD-2020-0488911,GILEAD,,,,A,M,Y,83.45,KG,20211025,,LW,US,US,SUSTIVA,Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Osteoarthritis;Osteonecrosis;Pain;Polyneuropathy;Renal cyst;Renal failure;Tooth loss;Vitamin D deficiency,181143495,OT,,,181143495,1,20000101,201803,7304,DAY,181143495,1,HIV infection
18116263,181162632,2,F,20100101,20211025,20200805,20211108,EXP,,US-GILEAD-2020-0488774,GILEAD,,45,YR,A,M,Y,80.726,KG,20211108,,LW,US,US,SUSTIVA,Angina pectoris;Anxiety;Arterial disorder;Asthenia;Bone density decreased;Chronic kidney disease;Depression;Dysstasia;Emotional distress;End stage renal disease;Gait disturbance;Jaw fracture;Nephrectomy;Pain;Periodontal disease;Renal failure;Renal injury,181162632,OT,,,181162632,1,20110224,20131007,956,DAY,181162632,1,HIV infection
18150978,181509784,4,F,20070403,20200817,20200814,20211122,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2020160069,VIIV,,,,N,M,Y,3.2,KG,20211122,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Foetal exposure during pregnancy;Hydrocele,181509784,OT,,,181509784,1,20070512,20070521,49,DAY,181509784,1,HIV infection
18150985,181509854,4,F,20070403,20200817,20200814,20211122,EXP,,FR-GLAXOSMITHKLINE-FR2020160069,GLAXOSMITHKLINE,,,,N,M,Y,3.2,KG,20211122,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Foetal exposure during pregnancy;Hydrocele,181509854,OT,,,181509854,1,20070512,20070521,49,DAY,181509854,1,HIV infection
18165528,181655285,5,F,20130601,20211011,20200818,20211019,EXP,,US-GILEAD-2020-0489964,GILEAD,,51,YR,A,M,Y,91.16,KG,20211019,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blindness;Blood creatinine increased;Bone disorder;Bone pain;Chronic kidney disease;Dry skin;Emotional distress;Hypokinesia;Pain;Pruritus;Rash;Renal impairment;Skin disorder,181655285,OT,,,181655285,1,200303,2012,1060,DAY,181655285,1,HIV infection
18176884,181768843,3,F,20080625,20211201,20200820,20211224,EXP,,US-GILEAD-2020-0491025,GILEAD,,58,YR,A,M,Y,111.57,KG,20211223,,LW,US,US,SUSTIVA,Depression;Diarrhoea;Emotional distress;Exercise tolerance decreased;Muscle spasms;Muscular weakness;Osteopenia;Osteoporosis;Pain;Protein urine present,181768843,OT,,,181768843,1,20060711,20190528,4704,DAY,181768843,1,HIV infection
18187253,181872535,5,F,,20211213,20200824,20211221,EXP,CA-MHPD-E2B_03070843,CA-Accord-196145,ACCORD,,,,,M,Y,,,20211221,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,181872535,DE,,,,,,,,,181872535,1,Product used for unknown indication
18349036,183490364,4,F,,20211220,20201006,20211227,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK189276,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20211227,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490364,OT,,,,,,,,,183490364,1,HIV infection
18349038,183490384,4,F,,20211220,20201006,20211227,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK189276,VIIV,,54,YR,,M,Y,,,20211227,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490384,OT,,,,,,,,,183490384,1,HIV infection
18349183,183491832,2,F,,20200921,20201006,20211118,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK194170,VIIV,,54,YR,,M,Y,,,20211118,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183491832,OT,,,,,,,,,183491832,1,Product used for unknown indication
18349187,183491872,2,F,,20200921,20201006,20211118,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK194170,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20211118,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,183491872,OT,,,,,,,,,183491872,1,Product used for unknown indication
18405930,184059304,4,F,,20211108,20201020,20211115,EXP,,ES-MYLANLABS-2020M1087834,MYLAN,"Basterreche N, Arrue A, Arnaiz A, Olivas O, Zumarraga M.. Repeat episode of late-onset psychosis associated with efavirenz.. Actas espanolas de psiquiatria.. 2020;48(4):181-183",47,YR,,M,Y,,,20211115,,HP,ES,ES,EFAVIRENZ,"Atrophy;Bipolar disorder;Central nervous system lesion;Delirium;Delusional perception;Hallucination, auditory;Insomnia;Mania;Psychiatric decompensation;Psychotic behaviour;Psychotic disorder;Psychotic symptom;Substance-induced psychotic disorder;Suicidal ideation",184059304,HO,,,184059304,1,,,4,YR,184059304,1,HIV infection
18441452,184414523,3,F,20171006,20211112,20201029,20211201,EXP,,US-GILEAD-2020-0501284,GILEAD,,61,YR,A,F,Y,,,20211201,,LW,US,US,SUSTIVA,Ankle fracture;Chronic kidney disease;Multiple fractures;Osteopenia,184414523,OT,,,184414523,1,20061231,20180101,4019,DAY,184414523,1,HIV infection
18442863,184428634,4,F,20150623,20211108,20201030,20211122,EXP,,US-GILEAD-2020-0501285,GILEAD,,67,YR,E,F,Y,,,20211121,,LW,US,US,SUSTIVA,Acute kidney injury;Bone loss;Chronic kidney disease;Osteoarthritis;Tooth loss,184428634,OT,,,184428634,1,20150206,20161018,620,DAY,184428634,1,HIV infection
18487650,184876506,6,F,20201027,20211130,20201111,20211203,EXP,,CN-GILEAD-2020-0503255,GILEAD,,,,A,M,Y,80,KG,20211203,,HP,CN,CN,TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAVIRENZ,Drug eruption;Pneumonia,184876506,HO,,,184876506,1,20201014,20201027,13,DAY,184876506,1,HIV infection
18553217,185532172,2,F,,20210930,20201127,20211013,EXP,,CA-ALVOGEN-2020-ALVOGEN-115293,ALVOGEN,,54,YR,,M,Y,,,20211013,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,185532172,OT,,,,,,,,,185532172,1,Bipolar disorder
18696971,186969714,4,F,20130823,20211011,20210104,20211024,EXP,,US-GILEAD-2020-0510869,GILEAD,,60,YR,A,M,Y,74.83,KG,20211023,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Chronic obstructive pulmonary disease;Depression;Dyspnoea;Emotional distress;End stage renal disease;Fatigue;Impaired work ability;Pain;Renal failure;Walking disability,186969714,HO,,,186969714,1,2004,2010,,,186969714,1,HIV infection
18727592,187275924,4,F,20191201,20211209,20210111,20211228,EXP,,US-GILEAD-2021-0511928,GILEAD,,74,YR,E,F,Y,,,20211228,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain upper;Arthralgia;CD4 lymphocytes abnormal;CD4 lymphocytes decreased;Cataract;Chronic obstructive pulmonary disease;Coronavirus infection;Dry age-related macular degeneration;Hiatus hernia;Memory impairment;Pulmonary function test decreased;Rib fracture;Visual impairment;Weight increased,187275924,DS,,,187275924,1,20210301,,,,187275924,1,HIV infection
18807345,188073452,2,F,20190101,20210929,20210128,20211001,PER,,US-GILEAD-2021-0513434,GILEAD,,,,A,M,Y,67.12,KG,20211001,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Mobility decreased;Pain,,,,,188073452,1,2001,2004,,,188073452,1,HIV infection
18832051,188320512,2,F,20171006,20211203,20210203,20211215,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-009871,BRISTOL MYERS SQUIBB,,61,YR,,F,Y,,,20211215,,LW,US,US,SUSTIVA,Ankle fracture;Chronic kidney disease;Multiple fractures;Osteopenia,188320512,OT,,,188320512,1,199812,20060801,3861,DAY,188320512,1,HIV infection
18863391,188633912,2,F,20150623,20211124,20210209,20211207,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-008411,BRISTOL MYERS SQUIBB,,71,YR,,F,Y,,,20211207,,LW,US,US,SUSTIVA,Acute kidney injury;Bone loss;Chronic kidney disease;Osteoarthritis;Tooth loss,188633912,OT,,,188633912,1,201502,20150206,621,DAY,188633912,1,HIV infection
18910584,189105842,2,F,,20211217,20210218,20211225,EXP,,CA-ROCHE-2772723,ROCHE,,54,YR,,M,Y,,,20211225,,HP,CA,,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189105842,DE,,,,,,,,,189105842,1,Bipolar disorder
18921190,189211903,3,F,,20211115,20210222,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013147,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211124,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189211903,OT,,,,,,,,,189211903,1,HIV infection
18923889,189238893,3,F,,20211115,20210222,20211125,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013552,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211125,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189238893,OT,,,,,,,,,189238893,1,Product used for unknown indication
18930097,189300972,2,F,,20211015,20210223,20211019,EXP,,CA-BAUSCH-BL-2021-005985,BAUSCH AND LOMB,,54,YR,,M,Y,,,20211019,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189300972,OT,,,,,,,,,189300972,1,Bipolar disorder
18958371,189583712,2,F,20210101,20211115,20210302,20211125,EXP,,CZ-VIIV HEALTHCARE LIMITED-CZ2021EME053964,VIIV,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending. Acta medicinae. 2021;10(14):50-52",53,YR,,M,Y,,,20211125,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,189583712,HO,,,189583712,1,199502,19990322,434,DAY,189583712,1,HIV infection
18958395,189583952,2,F,20210101,20211115,20210302,20211125,EXP,,CZ-GLAXOSMITHKLINE-CZ2021EME053964,GLAXOSMITHKLINE,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending. Acta medicinae. 2021;10(14):50-52",53,YR,,M,Y,,,20211125,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,189583952,OT,,,189583952,1,199502,19990322,434,DAY,189583952,1,HIV infection
18980892,189808922,2,F,20181214,20211126,20210308,20211204,EXP,,CZ-ABBVIE-21K-217-3801302-00,ABBVIE,,53,YR,,M,Y,,,20211204,,HP,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,189808922,OT,,,189808922,1,20000912,20161016,434,DAY,189808922,1,HIV infection
19000469,190004692,2,F,20181214,20211130,20210312,20211205,EXP,,CZ-JNJFOC-20210312901,JOHNSON AND JOHNSON,,53,YR,A,M,Y,,,20211206,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dysuria;HIV infection;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Toxicity to various agents;Urinary tract infection;Virologic failure,190004692,OT,,,190004692,1,20170214,19990322,434,DAY,190004692,1,HIV infection
19014954,190149542,2,F,20181214,20211129,20210316,20211207,EXP,,"CZ-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-088636",BOEHRINGER INGELHEIM,"Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending. Acta medicinae. 2021;10(14):50-52",53,YR,A,M,Y,,,20211208,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,190149542,HO,,,190149542,5,20050808,20061016,434,DAY,190149542,1,HIV infection
19025352,190253522,2,F,,20211217,20210318,20211223,EXP,,CA-ROCHE-2789224,ROCHE,,,,,M,Y,,,20211223,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,190253522,OT,,,,,,,,,190253522,1,Product used for unknown indication
19033823,190338232,2,F,20181214,20211201,20210319,20211208,EXP,,CZ-ROCHE-2786120,ROCHE,"Reporter known to authority, Fleischhans L, Jilich D, Machala L.. A Multidrug-resistant Form Of HIV Infection - A Hopeless Story With A Hopeful Ending.. Acta medicinae 2021;10(14):50-52.",53,YR,,M,Y,,,20211208,,MD,CZ,CZ,EFAVIRENZ,Drug ineffective;Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Multiple-drug resistance;Neoplasm progression;Pancytopenia;Pyrexia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,190338232,HO,,,190338232,4,20050808,20061016,435,DAY,190338232,1,HIV infection
19040818,190408182,2,F,,20211115,20210322,20211118,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-023401,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211118,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,190408182,OT,,,,,,,,,190408182,1,HIV infection
19059090,190590902,2,F,20210101,20211127,20210325,20211210,EXP,,CZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-022037,BRISTOL MYERS SQUIBB,,53,YR,,M,Y,,,20211210,,CN,CZ,CZ,EFAVIRENZ,Dyslipidaemia;Dysuria;Glucose tolerance impaired;HIV infection;Hypertension;Immunodeficiency;Kaposi's sarcoma;Laboratory test abnormal;Lymphoedema;Malignant neoplasm progression;Multiple-drug resistance;Pancytopenia;Skin lesion;Superinfection bacterial;Toxicity to various agents;Urinary tract infection;Virologic failure,190590902,OT,,,190590902,2,20000403,19990322,434,DAY,190590902,1,HIV infection
19074827,190748272,2,F,20100101,20210924,20210331,20211001,EXP,,US-GILEAD-2021-0523128,GILEAD,,,,A,M,Y,86.17,KG,20211001,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone demineralisation;Emotional distress;Gait disturbance;Infection;Osteoporosis;Pain,190748272,OT,,,190748272,1,2006,2010,,,190748272,1,HIV infection
19081584,190815845,5,F,20060602,20211208,20210331,20211216,EXP,,CA-AstraZeneca-2020SF04539,ASTRAZENECA,,44,YR,,M,Y,,,20211216,,MD,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,190815845,OT,,,190815845,1,20070729,20070730,2,DAY,190815845,1,Depression
19215421,192154212,2,F,20180114,20211014,20210504,20211025,EXP,,US-GILEAD-2021-0527871,GILEAD,,69,YR,E,F,Y,86.18,KG,20211025,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,192154212,OT,,,192154212,1,2008,201802,,,192154212,1,HIV infection
19221587,192215872,2,F,20080901,20211005,20210505,20211012,EXP,,US-GILEAD-2021-0527899,GILEAD,,70,YR,E,M,Y,72.56,KG,20211012,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Fall;Foot fracture;Gait disturbance;Hip fracture;Mobility decreased;Nephrolithiasis;Osteopenia;Osteoporosis;Pain,192215872,OT,,,192215872,1,200304,201108,,,192215872,1,HIV infection
19224072,192240722,2,F,20070101,20210915,20210505,20211005,PER,,US-GILEAD-2021-0527891,GILEAD,,50,YR,A,M,Y,95.24,KG,20211005,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Emotional distress;Osteopenia;Pain;Post-traumatic stress disorder,,,,,192240722,1,200709,201203,1728,DAY,192240722,1,HIV infection
19229151,192291512,2,F,20150527,20210924,20210506,20211010,PER,,US-GILEAD-2021-0528659,GILEAD,,,,,M,Y,85.27,KG,20211010,,LW,US,US,SUSTIVA,Anhedonia;Ankle fracture;Anxiety;Blood creatinine increased;Bone density decreased;Emotional distress;Fatigue;Foot fracture;Myalgia;Osteopenia;Pain,,,,,192291512,1,200601,201403,,,192291512,1,HIV infection
19396429,193964292,2,F,,20211012,20210610,20211018,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055869,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20211018,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,193964292,OT,,,,,,,,,193964292,1,Product used for unknown indication
19435745,194357452,2,F,20160101,20211123,20210618,20211208,EXP,,US-GILEAD-2021-0536637,GILEAD,,,,A,M,Y,,,20211208,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone density abnormal;Bone density decreased;Cardiac disorder;Depression;Dysstasia;Emotional distress;Osteopenia;Osteoporosis;Pain;Protein urine present;Proteinuria;Renal impairment;Renal injury,194357452,OT,,,194357452,1,2007,201605,,,194357452,1,HIV infection
19461093,194610935,5,F,,20211216,20210625,20211223,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-059435,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20211223,,HP,ES,ES,EFAVIRENZ,Hypertension;Thrombosis,194610935,OT,,,,,,,,,194610935,1,Antiretroviral therapy
19464465,194644654,4,F,,20211103,20210626,20211117,EXP,,ES-AUROBINDO-AUR-APL-2021-026748,AUROBINDO,"Aragon?s Eroles AM, Schoenenberger Arnaiz JA, Canomarr?n SM, Puig Ganau T, Morales Portillo A, Manonelles Fern?ndez A. Relaci?n entre niveles plasm?ticos de efavirenz y alteraciones lip?micas. Rev.OFIL?ILAPHAR. 2021;31 (1):64-69",,,A,,Y,,,20211117,,MD,ES,ES,EFAVIRENZ,Hypertension;No adverse event;Thrombosis,194644654,OT,,,,,,,,,194644654,1,Antiretroviral therapy
19465586,194655862,2,F,20111229,20211127,20210624,20211210,PER,,US-GILEAD-2021-0537451,GILEAD,,51,YR,A,M,Y,64.41,KG,20211210,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteopenia;Pain,,,,,194655862,1,2006,201108,,,194655862,1,HIV infection
19503738,195037382,2,F,,20211115,20210707,20211122,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065807,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211122,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,195037382,OT,,,,,,,,,195037382,1,HIV infection
19531557,195315573,3,F,,20211217,20210714,20211223,EXP,,CA-ROCHE-2866758,ROCHE,,,,,M,Y,,,20211223,,HP,CA,,SUSTIVA,Depression;Drug interaction,195315573,HO,,,,,,,,,195315573,1,Product used for unknown indication
19553865,195538654,4,F,20210613,20211108,20210715,20211115,EXP,,US-VIIV HEALTHCARE LIMITED-US2021AMR151556,VIIV,,59,YR,,M,Y,,,20211115,,MD,US,US,SUSTIVA,Central nervous system lesion;Cerebellar infarction;Cerebral infarction;Cerebrovascular accident;Coagulopathy;Dyspnoea;Folate deficiency;HIV associated nephropathy;Headache;Laboratory test abnormal;Major depression;Meningitis viral;Nephrolithiasis;Night sweats;Protein S deficiency;Pyrexia;Systemic viral infection;Thrombocytopenia;Thrombocytosis;Type 2 diabetes mellitus;Vision blurred;Vitamin B12 deficiency,195538654,HO,,,195538654,1,20210503,,,,195538654,1,Product used for unknown indication
19567906,195679062,2,F,,20211115,20210715,20211125,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-065846,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211125,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,195679062,OT,,,,,,,,,195679062,1,HIV infection
19581658,195816584,4,F,20210613,20211108,20210720,20211116,PER,,US-JNJFOC-20210731697,JOHNSON AND JOHNSON,,59,YR,A,M,Y,,,20211116,,MD,US,US,SUSTIVA,Central nervous system lesion;Cerebellar infarction;Cerebral infarction;Cerebrovascular accident;Coagulopathy;Dyspnoea;Folate deficiency;HIV associated nephropathy;Headache;Laboratory test abnormal;Major depression;Meningitis viral;Nephrolithiasis;Night sweats;Protein S deficiency;Pyrexia;Systemic viral infection;Thrombocytopenia;Thrombocytosis;Type 2 diabetes mellitus;Vision blurred;Vitamin B12 deficiency,195816584,HO,,,195816584,1,20210503,,,,195816584,1,Product used for unknown indication
19634933,196349332,2,F,20110101,20211122,20210730,20211204,PER,,US-GILEAD-2021-0541785,GILEAD,,,,A,M,Y,,,20211204,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Emotional distress;Hypertension;Pain;Pollakiuria;Renal impairment,,,,,196349332,1,2006,20180304,2330,DAY,196349332,1,HIV infection
19658313,196583132,2,F,20100101,20211112,20210804,20211209,EXP,,US-GILEAD-2021-0542328,GILEAD,,45,YR,A,M,Y,78.458,KG,20211209,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Emotional distress;Exercise tolerance decreased;Gait disturbance;Hip arthroplasty;Osteoporosis;Pain,196583132,HO,,,196583132,1,200802,2010,,,196583132,1,HIV infection
19660215,196602152,2,F,20180101,20211015,20210805,20211028,EXP,,US-GILEAD-2021-0542443,GILEAD,,,,A,M,Y,124.72,KG,20211028,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Pain,196602152,OT,,,196602152,1,20130520,201306,129,DAY,196602152,1,HIV infection
19660327,196603273,3,F,,20211007,20210805,20211019,EXP,,US-PFIZER INC-202100952123,PFIZER,,60,YR,,F,Y,,,20211019,,HP,US,US,EFAVIRENZ,Alopecia;Haemoglobin decreased;Hypocalcaemia,196603273,OT,,,196603273,1,20210713,,,,196603273,1,Breast cancer female
19661898,196618983,3,F,,20211209,20210805,20211220,EXP,,CA-APOTEX-2021AP028481,APOTEX,,54,YR,,M,Y,,,20211220,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,196618983,OT,,,,,,,,,196618983,1,HIV infection
19664910,196649102,2,F,20180101,20211111,20210805,20211123,EXP,,US-GILEAD-2021-0542366,GILEAD,,,,A,M,Y,86,KG,20211123,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Osteopenia;Pain,196649102,OT,,,196649102,1,2008,2015,,,196649102,1,HIV infection
19694193,196941932,2,F,20210701,20210805,20210813,20211130,EXP,,ZA-NOVOPROD-836698,NOVO NORDISK,,47,YR,,M,Y,,,20211130,,CN,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Death,196941932,DE,,,196941932,1,,202107,,,196941932,1,Diabetes mellitus
19734669,197346692,2,F,,20211217,20210824,20211223,EXP,,CA-ROCHE-2782429,ROCHE,,54,YR,,M,Y,,,20211223,,HP,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,197346692,HO,,,197346692,14,,,365,DAY,197346692,1,Depression
19744986,197449864,4,F,,20211207,20210825,20211214,EXP,,CA-009507513-2108CAN005807,MERCK,,54,YR,,M,Y,,,20211214,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,197449864,DE,,,,,,,,,197449864,1,HIV infection
19755697,197556972,2,F,20150501,20211214,20210827,20211229,EXP,,US-GILEAD-2021-0545324,GILEAD,,64,YR,A,M,Y,,,20211229,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Chronic kidney disease;Emotional distress;Erectile dysfunction;Gout;Hypertension;Pain;Renal failure,197556972,OT,,,197556972,1,2006,2016,,,197556972,1,HIV infection
19756236,197562362,2,F,,20210928,20210827,20211012,EXP,,CA-ALVOGEN-2021-ALVOGEN-117381,ALVOGEN,,54,YR,,M,Y,,,20211012,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197562362,OT,,,,,,,,,197562362,1,Bipolar disorder
19759214,197592142,2,F,,20211207,20210829,20211214,EXP,,CA-009507513-2108CAN006022,MERCK,,54,YR,,M,Y,,,20211214,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197592142,OT,,,,,,,,,197592142,1,Product used for unknown indication
19786994,197869942,2,F,20120101,20211124,20210903,20211203,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-084646,BRISTOL MYERS SQUIBB,,51,YR,,M,Y,,,20211203,,LW,US,US,SUSTIVA,Arthralgia;Arthropathy;Bone density abnormal;Bone density decreased;Multiple fractures;Musculoskeletal discomfort;Osteonecrosis;Osteoporosis;Tooth fracture;Tooth loss,197869942,OT,,,197869942,1,200807,2011,,,197869942,1,HIV infection
19865762,198657622,2,F,20160101,20211215,20210922,20211230,EXP,,US-GILEAD-2021-0548504,GILEAD,,60,YR,A,M,Y,,,20211230,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Emotional distress;Hypertension;Joint injury;Nephropathy;Osteoarthritis;Osteopenia;Osteoporosis;Pain;Protein urine present,198657622,OT,,,198657622,1,2006,201701,,,198657622,1,HIV infection
19882848,198828482,2,F,20210828,20210923,20210924,20211001,EXP,,RU-GILEAD-2021-0549987,GILEAD,,10,YR,C,M,Y,31,KG,20211001,,MD,RU,RU,EFAVIRENZ,Vomiting,198828482,DS,,,198828482,1,20210828,202109,3,WK,198828482,1,HIV infection
19883492,198834922,2,F,,20211015,20210926,20211021,EXP,,AU-ABBVIE-21K-008-4090300-00,ABBVIE,,,,,F,Y,,,20211021,,CN,AU,AU,EFAVIRENZ,Behaviour disorder;Central nervous system inflammation;Cerebellar syndrome;Chorea;Confusional state;Disorientation;Dysarthria;Dysdiadochokinesis;Gait disturbance;HIV-associated neurocognitive disorder;Hypophagia;Loss of personal independence in daily activities;Magnetic resonance imaging head abnormal;Meningitis viral;Meningoencephalitis viral;Parainfluenzae virus infection;Pathogen resistance;Rhinitis;Treatment noncompliance;Viral mutation identified,198834922,OT,,,,,,,,,198834922,1,Product used for unknown indication
19894699,198946992,2,F,,20211117,20210929,20211122,EXP,,CA-APOTEX-2021AP043233,APOTEX,,54,YR,,M,Y,,,20211122,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,198946992,OT,,,,,,,,,198946992,1,HIV infection
19903750,199037501,1,I,,20210921,20211001,20211001,EXP,,CA-APOTEX-2021AP043245,APOTEX,,54,YR,,M,Y,,,20211001,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199037501,OT,,,,,,,,,199037501,1,HIV infection
19903764,199037641,1,I,,20210914,20211001,20211001,EXP,,IN-CIPLA LTD.-2021IN06420,CIPLA,"Soneja M, Gupta N, Aggarwal A, Kodan P. Human immunodeficiency virus infection with multiple opportunistic infections: lessons learnt from a non-adherent patient. Oxford Medical Case Reports. 2021;3:79 to 81",,,,,Y,,,20211001,,HP,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Cachexia;Dehydration;Depression;Diarrhoea;Dysphagia;Electrolyte imbalance;Ichthyosis;Oral candidiasis;Treatment failure;Treatment noncompliance,199037641,HO,,,,,,,,,199037641,1,Antiretroviral therapy
19903925,199039253,3,F,20210613,20211108,20211001,20211115,EXP,,US-GLAXOSMITHKLINE-US2021AMR151556,GLAXOSMITHKLINE,,59,YR,,M,Y,,,20211115,,MD,US,US,SUSTIVA,Central nervous system lesion;Cerebellar infarction;Cerebral infarction;Cerebrovascular accident;Coagulopathy;Dyspnoea;Folate deficiency;HIV associated nephropathy;Headache;Laboratory test abnormal;Major depression;Meningitis viral;Nephrolithiasis;Night sweats;Protein S deficiency;Pyrexia;Systemic viral infection;Thrombocytopenia;Thrombocytosis;Type 2 diabetes mellitus;Vision blurred;Vitamin B12 deficiency,199039253,HO,,,199039253,1,20210503,,,,199039253,1,Product used for unknown indication
19904028,199040281,1,I,20201106,20210928,20211001,20211001,EXP,,ZA-STRIDES ARCOLAB LIMITED-2021SP028250,STRIDES,,,,,F,Y,,,20211001,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,199040281,OT,,,199040281,1,20200910,20200909,1281,DAY,199040281,1,Product used for unknown indication
19904111,199041111,1,I,20170501,20210922,20211001,20211001,EXP,,GB-TEVA-2021-GB-1958742,TEVA,,57,YR,A,F,Y,,,20211001,,MD,GB,GB,EFAVIRENZ,Drug interaction;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,199041111,OT,,,199041111,1,20100901,,,,199041111,1,HIV infection
19910547,199105471,1,I,20170501,20210922,20211004,20211004,EXP,,GB-AUROBINDO-AUR-APL-2021-040732,AUROBINDO,,57,YR,,F,Y,,,20211004,,MD,GB,GB,EFAVIRENZ,Drug interaction;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,199105471,OT,,,199105471,1,20100901,,,,199105471,1,HIV infection
19911577,199115771,1,I,20171015,20210927,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC204133,VIIV,,31,YR,,M,Y,67,KG,20211004,,MD,KR,KR,EFAVIRENZ,Appendicitis,199115771,HO,,,199115771,1,20170930,201511,,,199115771,1,HIV infection
19911589,199115891,1,I,20150904,20210927,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC203869,VIIV,,43,YR,,M,Y,64.5,KG,20211004,,MD,KR,KR,EFAVIRENZ,Lymphoma,199115891,HO,,,199115891,1,20150416,20150527,41,DAY,199115891,1,HIV infection
19911682,199116821,1,I,20150904,20210927,20211004,20211004,EXP,,KR-GLAXOSMITHKLINE-KR2021APC203869,GLAXOSMITHKLINE,,43,YR,,M,Y,64.5,KG,20211004,,MD,KR,KR,EFAVIRENZ,Lymphoma,199116821,HO,,,199116821,1,20150416,20150527,41,DAY,199116821,1,HIV infection
19911988,199119881,1,I,20130513,20210927,20211004,20211004,EXP,,KR-GLAXOSMITHKLINE-KR2021APC204139,GLAXOSMITHKLINE,,35,YR,,M,Y,56.7,KG,20211004,,MD,KR,KR,EFAVIRENZ,Conjunctivitis;Headache;Hyperbilirubinaemia;Myalgia;Pyrexia,199119881,OT,,,199119881,1,20130417,20130512,25,DAY,199119881,1,HIV infection
19911996,199119961,1,I,20130513,20210927,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC204139,VIIV,,35,YR,,M,Y,56.7,KG,20211004,,MD,KR,KR,EFAVIRENZ,Conjunctivitis;Headache;Hyperbilirubinaemia;Myalgia;Pyrexia,199119961,OT,,,199119961,1,20130417,20130512,25,DAY,199119961,1,HIV infection
19912698,199126981,1,I,20131007,20210927,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC203445,VIIV,,47,YR,,M,Y,64.7,KG,20211004,,MD,KR,KR,EFAVIRENZ,Cellulitis;Dyslipidaemia;Lipid metabolism disorder,199126981,OT,,,199126981,1,20130419,20131031,10,DAY,199126981,1,HIV infection
19912703,199127031,1,I,20131007,20210927,20211004,20211004,EXP,,KR-GLAXOSMITHKLINE-KR2021APC203445,GLAXOSMITHKLINE,,47,YR,,M,Y,64.7,KG,20211004,,MD,KR,KR,EFAVIRENZ,Cellulitis;Dyslipidaemia;Lipid metabolism disorder,199127031,OT,,,199127031,1,20130419,20131031,10,DAY,199127031,1,HIV infection
19913202,199132021,1,I,20160108,20210927,20211004,20211004,EXP,,KR-VIIV HEALTHCARE LIMITED-KR2021APC204117,VIIV,,53,YR,,M,Y,83,KG,20211004,,MD,KR,KR,EFAVIRENZ,Depression;Insomnia;Macular oedema;Periodontitis;Retinal detachment,199132021,OT,,,199132021,1,20121204,20160111,866,DAY,199132021,1,HIV infection
19913206,199132061,1,I,20160108,20210927,20211004,20211004,EXP,,KR-GLAXOSMITHKLINE-KR2021APC204117,GLAXOSMITHKLINE,,53,YR,,M,Y,83,KG,20211004,,MD,KR,KR,EFAVIRENZ,Depression;Insomnia;Macular oedema;Periodontitis;Retinal detachment,199132061,OT,,,199132061,1,20121204,20160111,866,DAY,199132061,1,HIV infection
19913795,199137951,1,I,20200701,20210927,20211004,20211004,EXP,,CH-VIIV HEALTHCARE LIMITED-CH2021EME203313,VIIV,,,,A,M,Y,,,20211004,,MD,CH,CH,EFAVIRENZ,Acute kidney injury;Hepatosplenomegaly;Immune system disorder;Pancytopenia;Peripheral sensory neuropathy;Visceral leishmaniasis;Weight decreased,199137951,OT,,,199137951,1,201911,202007,,,199137951,1,HIV infection
19913803,199138031,1,I,20200701,20210927,20211004,20211004,EXP,,CH-GLAXOSMITHKLINE-CH2021EME203313,GLAXOSMITHKLINE,,,,A,M,Y,,,20211004,,MD,CH,CH,EFAVIRENZ,Acute kidney injury;Hepatosplenomegaly;Immune system disorder;Pancytopenia;Peripheral sensory neuropathy;Visceral leishmaniasis;Weight decreased,199138031,OT,,,199138031,1,201911,202007,,,199138031,1,HIV infection
19923817,199238171,1,I,,20211004,20211006,20211006,EXP,,US-GILEAD-2021-0551366,GILEAD,,,,A,F,Y,,,20211006,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Lung disorder;Pneumocystis jirovecii pneumonia,199238171,OT,,,199238171,1,,2018,,,199238171,1,HIV infection
19928214,199282141,1,I,,20210922,20211007,20211007,EXP,,CA-ALVOGEN-2021-ALVOGEN-117617,ALVOGEN,,54,YR,,M,Y,,,20211007,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,199282141,DE,,,,,,,,,199282141,1,Bipolar disorder
19930845,199308451,1,I,20201106,20210927,20211008,20211008,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-099507,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20211008,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,199308451,OT,,,199308451,1,20200910,20200909,1281,DAY,199308451,1,Antiretroviral therapy
19931364,199313641,1,I,20050101,20211004,20211007,20211007,EXP,,FR-MYLANLABS-2021M1069430,MYLAN,,65,YR,,M,Y,,,20211007,,MD,FR,FR,SUSTIVA,Drug resistance;Virologic failure,199313641,OT,,,199313641,1,20020701,20060601,46,MON,199313641,1,HIV infection
19934204,199342041,1,I,,20210930,20211008,20211008,EXP,,CA-MYLANLABS-2021M1071033,MYLAN,,54,YR,,M,Y,,,20211008,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,199342041,OT,,,,,,,,,199342041,1,Bipolar disorder
19934696,199346961,1,I,,20211005,20211008,20211008,EXP,,CA-ABBVIE-21K-028-4108072-00,ABBVIE,,54,YR,,M,Y,,,20211008,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,199346961,OT,,,,,,,,,199346961,1,HIV infection
19934817,199348171,1,I,,20211005,20211008,20211008,EXP,,CA-ABBVIE-21K-028-4109834-00,ABBVIE,,54,YR,,M,Y,,,20211008,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,199348171,OT,,,,,,,,,199348171,1,Product used for unknown indication
19937515,199375151,1,I,,20211005,20211011,20211011,EXP,,CA-ABBVIE-21K-028-4107809-00,ABBVIE,,54,YR,,M,Y,,,20211011,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,199375151,OT,,,,,,,,,199375151,1,Product used for unknown indication
19937527,199375271,1,I,,20211005,20211011,20211011,EXP,,CA-ABBVIE-21K-028-4107746-00,ABBVIE,,54,YR,,M,Y,,,20211011,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199375271,OT,,,,,,,,,199375271,1,Product used for unknown indication
19937752,199377521,1,I,20200101,20210928,20211011,20211011,EXP,,ZA-CIPLA LTD.-2021ZA06600,CIPLA,,,,,,Y,,,20211011,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Exposure during pregnancy,199377521,OT,,,199377521,1,20200910,20200909,42,MON,199377521,1,Product used for unknown indication
19939236,199392361,1,I,20201106,20210927,20211011,20211011,EXP,,ZA-AUROBINDO-AUR-APL-2021-041056,AUROBINDO,,,,,F,Y,,,20211011,,HP,ZA,ZA,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,199392361,OT,,,199392361,1,20200910,20200909,1281,DAY,199392361,1,Product used for unknown indication
19940735,199407351,1,I,20020101,20210927,20211011,20211011,EXP,,FR-MYLANLABS-2021M1067533,MYLAN,"Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM et al... Renal Tubular Dysfunction Associated with Tenofovir Therapy: Report of 7 Cases.. J Acquir Immune Defic Syndr. 2004;35(3):269-73",48,YR,,F,Y,42,KG,20211011,,HP,FR,FR,EFAVIRENZ,Acquired aminoaciduria;Argininosuccinate synthetase deficiency;Creatinine renal clearance decreased;Hypophosphataemia;Myalgia;Nephropathy toxic;Paraesthesia;Proteinuria;Renal glycosuria;Renal tubular dysfunction,199407351,OT,,,199407351,1,200108,,,,199407351,1,HIV infection
19945221,199452211,1,I,20210915,20211005,20211012,20211012,EXP,,TH-SA-2021SA332305,SANOFI AVENTIS,,28,YR,A,F,Y,,,20211012,,HP,TH,TH,EFAVIRENZ + EMTRICITABINE + TENOFOVIR [EFAVIRENZ;EMTRICITABINE;TENOFOV,Conjunctivitis;Drug hypersensitivity;Dyspnoea;Hepatitis;Nausea;Pyrexia;Vomiting,199452211,OT,,,199452211,1,20210804,20210929,57,DAY,199452211,1,Tuberculosis
19945398,199453981,1,I,,20211004,20211012,20211012,EXP,,CA-ABBVIE-21K-028-4106370-00,ABBVIE,,54,YR,,M,Y,,,20211012,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199453981,OT,,,,,,,,,199453981,1,Bipolar disorder
19945467,199454671,1,I,,20211006,20211012,20211012,EXP,,LV-MYLANLABS-2021M1070855,MYLAN,,41,YR,,M,Y,,,20211012,,MD,LV,LV,EFAVIRENZ,Dizziness;Hyperlipidaemia;Nightmare;Pulmonary hypertension,199454671,OT,,,,,,,,,199454671,1,HIV infection
19945615,199456151,1,I,,20210930,20211012,20211012,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-101122,BRISTOL MYERS SQUIBB,,58,YR,,M,Y,,,20211012,,CN,GB,GB,EFAVIRENZ,Renal failure,199456151,OT,,,199456151,1,20120601,,,,199456151,1,HIV infection
19948549,199485491,1,I,,20211012,20211013,20211013,EXP,IS-IMA-4919,IS-GILEAD-2021-0552407,GILEAD,,,,A,M,Y,,,20211013,,PH,IS,IS,EFAVIRENZ,Abdominal pain;Acute kidney injury;Asthenia;Chest pain;Diarrhoea;Fanconi syndrome;Hypoaesthesia;Hypokalaemia;Hypophosphataemia;Metabolic acidosis;Osteoporosis;Rib fracture;Vitamin B12 deficiency;Vitamin D deficiency,199485491,DS,,,199485491,1,20050503,,,,199485491,1,HIV infection
19949662,199496622,2,F,,20211011,20211013,20211121,EXP,,CA-009507513-2110CAN002720,MERCK,,,,,M,Y,,,20211121,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,199496622,HO,,,,,,,,,199496622,1,Product used for unknown indication
19951029,199510291,1,I,,20210930,20211014,20211014,EXP,,GB-AUROBINDO-AUR-APL-2021-042245,AUROBINDO,,58,YR,,M,Y,,,20211014,,MD,GB,GB,EFAVIRENZ,Renal failure,199510291,OT,,,199510291,1,20120601,,,,199510291,1,HIV infection
19953657,199536571,1,I,,20211008,20211013,20211013,EXP,,IT-MYLANLABS-2021M1071657,MYLAN,,65,YR,,M,Y,,,20211013,,HP,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective,199536571,OT,,,,,,,,,199536571,1,HIV infection
19959618,199596181,1,I,,20211011,20211015,20211015,EXP,,IT-MYLANLABS-2021M1071995,MYLAN,,52,YR,,F,Y,,,20211015,,HP,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Genotype drug resistance test positive,199596181,OT,,,,,,,,,199596181,1,HIV infection
19959620,199596201,1,I,,20211011,20211015,20211015,EXP,,IT-MYLANLABS-2021M1071993,MYLAN,,36,YR,,M,Y,,,20211015,,HP,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Genotype drug resistance test positive,199596201,OT,,,,,,,,,199596201,1,HIV infection
19961937,199619371,1,I,,20211006,20211018,20211018,EXP,,MW-CIPLA LTD.-2021MW06795,CIPLA,"Brasher WP, Bvumbwe M, Kazembe PN.. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi Medical Journal. 2020;32 (4):229 to 231",,,,,Y,,,20211018,,HP,MW,MW,EFAVIRENZ,Ataxia;Confusional state;Diplopia;Dysdiadochokinesis;Toxicity to various agents,199619371,HO,,,199619371,1,2012,,,,199619371,1,HIV infection
19961958,199619581,1,I,,20211012,20211018,20211018,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106097,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20211018,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199619581,DE,,,,,,,,,199619581,1,Product used for unknown indication
19962107,199621071,1,I,,20211012,20211018,20211018,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106111,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20211018,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199621071,DE,,,,,,,,,199621071,1,Product used for unknown indication
19963156,199631561,1,I,,20211012,20211018,20211018,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-107103,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20211018,,HP,CA,CA,SUSTIVA,Depression;Drug ineffective,199631561,DE,,,,,,,,,199631561,1,Product used for unknown indication
19964056,199640562,2,F,,20211026,20211018,20211102,EXP,,ZA-GILEAD-2021-0552643,GILEAD,"Loveday M., Hughes J., Sunkari B., Master I., Hlangu S., Reddy T., Chotoo S., Green N., Seddon J.. Maternal and Infant Outcomes among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect Dis.. 2021;72:1158-1168. doi:10.1093/cid/ciaa189",,,I,M,Y,,,20211102,,HP,ZA,ZA,EFAVIRENZ,Ehlers-Danlos syndrome;Foetal exposure during pregnancy,199640562,CA,,,199640562,1,2015,,,,199640562,1,HIV infection
19964059,199640592,2,F,,20211026,20211018,20211102,EXP,,ZA-GILEAD-2021-0552640,GILEAD,"Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T, Chotoo S, Green N, Seddon J. Maternal and Infant Outcomes among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect Dis.. 2021;72:1158-1168. doi:10.1093/cid/ciaa189",,,I,,Y,,,20211102,,HP,ZA,ZA,EFAVIRENZ,Congenital umbilical hernia;Foetal exposure during pregnancy,199640592,CA,,,,,,,,,199640592,1,HIV infection
19964781,199647811,1,I,,20211012,20211018,20211018,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-107042,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211018,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199647811,DE,,,,,,,,,199647811,1,Product used for unknown indication
19967368,199673681,1,I,,20040719,20211019,20211019,EXP,,US-GILEAD-2004-0007278,GILEAD,,,,N,M,Y,,,20211019,,HP,US,US,SUSTIVA,Meningomyelocele,199673681,CA,,,199673681,1,20030310,20040219,347,DAY,199673681,1,HIV infection
19969617,199696171,1,I,,20211014,20211019,20211019,EXP,,FR-MYLANLABS-2021M1073241,MYLAN,"Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM et al.. Renal Tubular Dysfunction Associated with Tenofovir Therapy: Report of 7 Cases.. J Acquir Immune Defic Syndr. 2004;35(3):269-73",56,YR,,F,Y,56,KG,20211019,,MD,FR,FR,EFAVIRENZ,Creatinine renal clearance decreased;Glycosuria;Hypophosphataemia;Nephropathy toxic;Proteinuria,199696171,OT,,,199696171,1,202105,2002,11,MON,199696171,1,HIV infection
19974654,199746542,2,F,,20211013,20211020,20211123,EXP,,CA-009507513-2110CAN004097,MERCK,,,,,M,Y,,,20211123,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,199746542,OT,,,,,,,,,199746542,1,Product used for unknown indication
19976642,199766421,1,I,,20211018,20211021,20211021,EXP,,CA-BAUSCH-BL-2021-035051,BAUSCH AND LOMB,,,,,M,Y,,,20211021,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199766421,DE,,,,,,,,,199766421,1,Product used for unknown indication
19976643,199766431,1,I,,20211018,20211021,20211021,EXP,,CA-BAUSCH-BL-2021-035052,BAUSCH AND LOMB,,,,,M,Y,,,20211021,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199766431,DE,,,,,,,,,199766431,1,Product used for unknown indication
19977951,199779512,2,F,20210101,20211110,20211020,20211117,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME212973,VIIV,,,,,M,Y,,,20211117,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,199779512,OT,,,199779512,2,2018,201911,,,199779512,1,HIV infection
19978643,199786432,2,F,20210101,20211110,20211020,20211117,EXP,,GB-GLAXOSMITHKLINE-GB2021EME212973,GLAXOSMITHKLINE,,,,,M,Y,,,20211117,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,199786432,OT,,,199786432,2,2018,201911,,,199786432,1,HIV infection
19986690,199866901,1,I,,20211018,20211022,20211022,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK218790,VIIV,,,,,M,Y,,,20211022,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199866901,DE,,,,,,,,,199866901,1,Product used for unknown indication
19986693,199866931,1,I,,20211018,20211022,20211022,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK218650,VIIV,,,,,M,Y,,,20211022,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199866931,DE,,,,,,,,,199866931,1,Product used for unknown indication
19987144,199871441,1,I,,20211018,20211022,20211022,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK218790,GLAXOSMITHKLINE,,,,,M,Y,,,20211022,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199871441,DE,,,,,,,,,199871441,1,Product used for unknown indication
19987166,199871661,1,I,,20211018,20211022,20211022,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK218650,GLAXOSMITHKLINE,,,,,M,Y,,,20211022,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199871661,DE,,,,,,,,,199871661,1,Product used for unknown indication
19987416,199874161,1,I,,20211012,20211023,20211023,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106842,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20211023,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,199874161,HO,,,,,,,,,199874161,1,Product used for unknown indication
19987631,199876311,1,I,,20211017,20211022,20211022,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN214594,VIIV,,69,YR,,M,Y,,,20211022,,MD,JP,JP,EFAVIRENZ,Angina pectoris;Blood HIV RNA increased;Blood creatinine increased;Diabetes mellitus;Hypertension;Protein urine;Renal disorder,199876311,OT,,,,,,,,,199876311,1,Acquired immunodeficiency syndrome
19987636,199876361,1,I,,20211017,20211022,20211022,EXP,,JP-GLAXOSMITHKLINE-JP2021JPN214594,GLAXOSMITHKLINE,,69,YR,,M,Y,,,20211022,,MD,JP,JP,EFAVIRENZ,Angina pectoris;Blood HIV RNA increased;Blood creatinine increased;Diabetes mellitus;Hypertension;Protein urine;Renal disorder,199876361,OT,,,,,,,,,199876361,1,Acquired immunodeficiency syndrome
19987713,199877131,1,I,,20211012,20211023,20211023,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-107393,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20211023,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,199877131,OT,,,,,,,,,199877131,1,Product used for unknown indication
19994231,199942311,1,I,,20211020,20211026,20211026,EXP,,CA-ROCHE-2941247,ROCHE,,54,YR,,M,Y,,,20211026,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,199942311,DE,,,,,,,,,199942311,1,Bipolar disorder
19994721,199947211,1,I,,20211025,20211026,20211026,EXP,,US-GILEAD-2021-0554050,GILEAD,,,,E,F,Y,,,20211026,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Near death experience;Pneumonia,199947211,HO,,,,,,,,,199947211,1,HIV infection
20003856,200038562,2,F,20210101,20211119,20211028,20211203,EXP,,GB-AUROBINDO-AUR-APL-2021-043509,AUROBINDO,,71,YR,,M,Y,,,20211203,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,200038562,OT,,,200038562,1,20191114,201911,,,200038562,1,HIV infection
20003901,200039011,1,I,,20211021,20211027,20211027,EXP,,FR-MYLANLABS-2021M1075506,MYLAN,,29,YR,,,Y,,,20211027,,CN,FR,FR,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Depression;Drug ineffective;Negative thoughts;Psychiatric symptom;Viral load increased,200039011,OT,,,200039011,1,202012,,,,200039011,1,Product used for unknown indication
20005496,200054962,2,F,20121201,20211103,20211028,20211112,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-108480,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,,,20211112,,MD,PT,PT,EFAVIRENZ,Dyslipidaemia;Weight increased,200054962,OT,,,200054962,1,201012,201212,,,200054962,1,Product used for unknown indication
20010039,200100392,2,F,,20211113,20211028,20211123,EXP,,CA-TEVA-2021-CA-1969608,TEVA,,54,YR,A,M,Y,,,20211123,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,200100392,OT,,,,,,,,,200100392,1,HIV infection
20010155,200101551,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969621,TEVA,,54,YR,A,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200101551,HO,,,,,,,,,200101551,1,HIV infection
20010307,200103071,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969604,TEVA,,54,YR,A,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,200103071,OT,,,,,,,,,200103071,1,HIV infection
20010344,200103441,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969611,TEVA,,,,,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200103441,OT,,,,,,,,,200103441,1,Product used for unknown indication
20010426,200104261,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1970485,TEVA,,54,YR,A,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200104261,DE,,,,,,,,,200104261,1,Bipolar disorder
20010474,200104741,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969615,TEVA,,54,YR,A,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200104741,DE,,,,,,,,,200104741,1,HIV infection
20010477,200104771,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969630,TEVA,,54,YR,A,M,Y,,,20211028,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,200104771,OT,,,,,,,,,200104771,1,HIV infection
20010478,200104781,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969673,TEVA,,54,YR,A,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,200104781,DE,,,,,,,,,200104781,1,HIV infection
20010487,200104871,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1970475,TEVA,,,,,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200104871,DE,,,,,,,,,200104871,1,Product used for unknown indication
20010517,200105171,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1970500,TEVA,,,,,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200105171,OT,,,,,,,,,200105171,1,Product used for unknown indication
20010827,200108271,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969602,TEVA,,,,,M,Y,,,20211028,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200108271,DE,,,,,,,,,200108271,1,Product used for unknown indication
20010916,200109161,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1970457,TEVA,,,,,M,Y,,,20211029,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,200109161,DE,,,,,,,,,200109161,1,Product used for unknown indication
20010924,200109241,1,I,,20211020,20211028,20211028,EXP,,CA-TEVA-2021-CA-1969598,TEVA,,54,YR,A,M,Y,,,20211029,,HP,,CA,SUSTIVA,Depression;Drug interaction,200109241,OT,,,,,,,,,200109241,1,HIV infection
20030180,200301801,1,I,,20211022,20211103,20211103,EXP,,SA-GLAXOSMITHKLINE-SA2021GSK219680,GLAXOSMITHKLINE,,,,A,F,Y,,,20211103,,MD,SA,SA,EFAVIRENZ,Exposure during pregnancy;Live birth;Pathogen resistance,200301801,OT,,,,,,,,,200301801,1,HIV infection
20030181,200301811,1,I,,20211022,20211103,20211103,EXP,,SA-VIIV HEALTHCARE LIMITED-SA2021GSK219680,VIIV,,,,A,F,Y,,,20211103,,MD,SA,SA,EFAVIRENZ,Exposure during pregnancy;Live birth;Pathogen resistance,200301811,OT,,,,,,,,,200301811,1,HIV infection
20031273,200312731,1,I,,20211026,20211103,20211103,EXP,,TW-MYLANLABS-2021M1080284,MYLAN,"Kao S-W, Liu Z-H, Wu T-S, Ku SW-W, Tsai C-L, Shie S-S, et al. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: An observational study in a tertiary hospital in Northern Taiwan, 2017-19. J-Antimicrob-Chemother 2021;76(3):722-728.",,,,,Y,,,20211103,,HP,TW,TW,EFAVIRENZ,Drug resistance,200312731,OT,,,,,,,,,200312731,1,HIV infection
20034515,200345151,1,I,20110201,20211029,20211104,20211104,EXP,,US-GILEAD-2021-0554805,GILEAD,,38,YR,A,M,Y,,,20211104,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Back pain;Cardiac failure;Depression;Dyspnoea exertional;Fatigue;Fluid retention;Hyperhidrosis;Intracardiac thrombus;Stress;Tuberculosis;Weight decreased,200345151,OT,,,200345151,1,,20140101,,,200345151,1,HIV infection
20035070,200350701,1,I,,20211029,20211104,20211104,EXP,,IT-MYLANLABS-2021M1079507,MYLAN,"Oltolini C, Ripa M, Greco R, Nozza S, Corti C, Peccatori J, et al.. Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier. Transplant Infectious Disease. 2021;23(3):1-4",57,YR,,F,Y,,,20211104,,HP,IT,IT,EFAVIRENZ,Drug ineffective;Herpes virus infection;Pancytopenia;Pneumonia bacterial;Product use in unapproved indication,200350701,OT,,,,,,,,,200350701,1,Prophylaxis against graft versus host disease
20041342,200413421,1,I,,20211029,20211107,20211107,EXP,,KZ-HETERO-HET2021KZ02059,HETERO,,,,,,Y,,,20211108,,HP,KZ,KZ,EFAVIRENZ;EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Depressed level of consciousness;Headache;Malaise,200413421,OT,,,,,,,,,200413421,1,HIV infection WHO clinical stage I
20044583,200445831,1,I,,20211029,20211108,20211108,EXP,,IT-MYLANLABS-2021M1081056,MYLAN,,,,,M,Y,,,20211108,,MD,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Hallucination;Nausea;Product substitution issue;Vomiting,200445831,OT,,,,,,,,,200445831,1,HIV infection
20044584,200445841,1,I,,20211029,20211108,20211108,EXP,,IT-MYLANLABS-2021M1081059,MYLAN,,,,,M,Y,,,20211108,,MD,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Hallucination;Nausea;Product substitution issue;Vomiting,200445841,OT,,,,,,,,,200445841,1,HIV infection
20044586,200445861,1,I,,20211029,20211108,20211108,EXP,,IT-MYLANLABS-2021M1081058,MYLAN,,,,,M,Y,,,20211108,,MD,IT,IT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Hallucination;Nausea;Product substitution issue;Vomiting,200445861,OT,,,,,,,,,200445861,1,HIV infection
20044841,200448411,1,I,,20211027,20211108,20211108,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2021GSK223294,VIIV,"Kouamou V, Mavetera J, Manasa J, Ndhlovu CE, Katzenstein D, Mcgregor AM et al.. Pretreatment HIV Drug Resistance among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?. AIDS Research and Human Retroviruses. 2021;37 (10):776-783",,,A,M,Y,,,20211108,,HP,ZW,ZW,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,200448411,OT,,,200448411,1,201001,201003,,,200448411,1,HIV infection
20044842,200448421,1,I,,20211027,20211108,20211108,EXP,,ZW-GLAXOSMITHKLINE-ZW2021GSK223294,GLAXOSMITHKLINE,"Kouamou V, Mavetera J, Manasa J, Ndhlovu CE, Katzenstein D, Mcgregor AM et al.. Pretreatment HIV Drug Resistance among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?. AIDS Research and Human Retroviruses. 2021;37 (10):776-783",,,A,M,Y,,,20211108,,HP,ZW,ZW,EFAVIRENZ,Pathogen resistance;Treatment noncompliance;Viral mutation identified,200448421,OT,,,200448421,1,201001,201003,,,200448421,1,HIV infection
20049700,200497001,1,I,,20211028,20211109,20211109,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-113592,BRISTOL MYERS SQUIBB,"Momen SE, Diaz-Cano S, Walsh S, Creamer D. Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms:facial edema aligns to the severe phenotype. Journal of the American Academy of Dermatology. 2021;85(3):645-52",50,YR,,M,Y,,,20211109,,MD,GB,GB,EFAVIRENZ,Drug reaction with eosinophilia and systemic symptoms,200497001,HO,,,,,,,,,200497001,1,HIV infection
20057137,200571372,2,F,20020605,20211220,20211111,20211223,EXP,,JP-GLAXOSMITHKLINE-A20032850,GLAXOSMITHKLINE,,43,YR,,M,Y,,,20211223,,MD,JP,JP,EFAVIRENZ,Blood uric acid increased;Cataract;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Hyperuricaemia;Lipoatrophy;Otitis media,200571372,OT,,,200571372,1,20010627,20030331,642,DAY,200571372,1,Acquired immunodeficiency syndrome
20057140,200571402,2,F,20020605,20211220,20211111,20211223,EXP,,JP-VIIV HEALTHCARE LIMITED-A20032850,VIIV,,43,YR,,M,Y,,,20211223,,MD,JP,JP,EFAVIRENZ,Blood uric acid increased;Cataract;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Hyperuricaemia;Lipoatrophy;Otitis media,200571402,HO,,,200571402,1,20010627,20030331,642,DAY,200571402,1,Acquired immunodeficiency syndrome
20057185,200571851,1,I,20170401,20211101,20211111,20211111,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2021APC230304,VIIV,,29,YR,,M,Y,,,20211111,,MD,TW,TW,EFAVIRENZ,Mesenteric vein thrombosis;Rash,200571851,OT,,,,,,,,,200571851,1,Product used for unknown indication
20057186,200571861,1,I,20130101,20211101,20211111,20211111,EXP,,TW-VIIV HEALTHCARE LIMITED-TW2021APC230919,VIIV,,,,,,Y,,,20211111,,MD,TW,TW,EFAVIRENZ,Hepatitis;Urticaria,200571861,OT,,,200571861,1,201212,201308,,,200571861,1,Product used for unknown indication
20057395,200573951,1,I,,20211108,20211111,20211111,EXP,,UG-GILEAD-2021-0556212,GILEAD,"Kiragga AN, Twinomuhwezi E, Banturaki G, Achieng M, Nampala J, Bagaya I, Kigozi J, Castelnuovo B, Musick B, Hazra R., Yiannoutsos C, Wools-Kaloustian K. Outcomes of retained and disengaged pregnant women living with HIV in Uganda. PLoS One.. 2021;16(5):unk. doi:10.1371/journal.pone.0251413",,,A,F,Y,,,20211111,,HP,UG,UG,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,200573951,OT,,,,,,,,,200573951,1,HIV infection
20058274,200582741,1,I,20201111,20211104,20211111,20211111,EXP,,TH-SA-2021SA165420,SANOFI AVENTIS,,27,YR,A,M,Y,,,20211111,,MD,TH,TH,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Alanine aminotransferase increased;Aspartate aminotransferase increased;Autoimmune hepatitis;Bicytopenia;Blood albumin decreased;Blood bilirubin increased;Clostridium difficile infection;Condition aggravated;Decreased appetite;Drug-induced liver injury;Dyspnoea;Eye colour change;Fungaemia;Gallbladder cholesterolosis;Hepatic steatosis;Hypercalcaemia;Hyponatraemia;Jaundice;Oedema peripheral;Peripheral swelling;Pneumonia;Pneumonia legionella;Pneumonia necrotising;Pneumothorax;Productive cough;Pyrexia;Respiratory failure;Steroid diabetes;Systemic inflammatory response syndrome;Thrombocytopenia;Vomiting;Weight decreased;Weight increased,200582741,LT,,,200582741,1,20200829,20201115,79,DAY,200582741,1,Latent tuberculosis
20067881,200678811,1,I,,20211103,20211115,20211115,EXP,,JP-MACLEODS PHARMACEUTICALS US LTD-MAC2021033336,MACLEODS,"Hamaya E, Kamekura N, Fujisawa T.. Suspected bradycardia due to interactions between HIV protease inhibitors and lidocaine: a case report. Journal of Dental Anesthesia and Pain Medicine. 2021;21(5):475-477",,,,,Y,,,20211115,,HP,JP,JP,EFAVIRENZ,Bradycardia;Drug interaction,200678811,OT,,,200678811,6,,,126,MIN,200678811,1,Ventricular extrasystoles
20069298,200692981,1,I,,20211105,20211115,20211115,EXP,,CA-PFIZER INC-202101538370,PFIZER,,54,YR,,M,Y,,,20211115,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,200692981,HO,,,200692981,17,,,365,DAY,200692981,1,Bipolar disorder
20069912,200699121,1,I,,20211104,20211115,20211115,EXP,,KE-GLAXOSMITHKLINE-KE2021GSK233760,GLAXOSMITHKLINE,,,,,,Y,,,20211115,,MD,KE,KE,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,200699121,OT,,,,,,,,,200699121,1,HIV infection
20069923,200699231,1,I,,20211104,20211115,20211115,EXP,,KE-VIIV HEALTHCARE LIMITED-KE2021GSK233760,VIIV,,,,,,Y,,,20211115,,MD,KE,KE,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,200699231,OT,,,,,,,,,200699231,1,HIV infection
20073094,200730941,1,I,20030101,20211109,20211116,20211116,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2021EME232520,VIIV,,,,A,M,Y,,,20211116,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,200730941,OT,,,200730941,1,1997,,,,200730941,1,HIV infection
20073096,200730961,1,I,20080101,20211109,20211116,20211116,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2021EME232447,VIIV,,,,A,M,Y,,,20211116,,MD,DE,DE,EFAVIRENZ,Pathogen resistance,200730961,OT,,,200730961,1,1997,,,,200730961,1,HIV infection
20073105,200731051,1,I,20030101,20211109,20211116,20211116,EXP,,DE-GLAXOSMITHKLINE-DE2021EME232520,GLAXOSMITHKLINE,,,,A,M,Y,,,20211116,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,200731051,OT,,,200731051,1,1997,,,,200731051,1,HIV infection
20073106,200731061,1,I,20080101,20211109,20211116,20211116,EXP,,DE-GLAXOSMITHKLINE-DE2021EME232447,GLAXOSMITHKLINE,,,,A,M,Y,,,20211116,,MD,DE,DE,EFAVIRENZ,Pathogen resistance,200731061,OT,,,200731061,1,1997,,,,200731061,1,HIV infection
20076456,200764561,1,I,,20211105,20211116,20211116,EXP,,CO-VIIV HEALTHCARE LIMITED-CO2021GSK193982,VIIV,"Garc?a-Ortiz J, Villamil-Morales IM, Lopez-Garcia JC. Nutritional status of pediatric patients living with human immunodeficiency virus in bogota, colombia. Infectio. 2021;26 (1):61-66",,,,M,Y,29,KG,20211116,,MD,CO,CO,EFAVIRENZ,Pathogen resistance;Viral mutation identified;Virologic failure,200764561,OT,,,200764561,1,20150406,201508,,,200764561,2,HIV infection
20081561,200815611,1,I,,20211108,20211117,20211117,EXP,,ZA-GILEAD-2021-0556201,GILEAD,"Malaba TR, Myer L, Gray C, Newell ML. Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS). BMJ Open.. 2021;11(9):unk. doi:10.1136/bmjopen-2020-047133",,,A,F,Y,,,20211117,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Foetal death;Maternal exposure during pregnancy,200815611,OT,,,,,,,,,200815611,1,HIV infection
20083738,200837381,1,I,,20211108,20211118,20211118,EXP,,US-CIPLA LTD.-2021US07568,CIPLA,"Seo H, Ahuja T, Jen S.P, Green D, Papadopoulos J.. Direct oral anticoagulants versus warfarin in people living with human immunodeficiency virus.. International Journal of STD + AIDS. 2021;0(0):1-10",,,,,Y,,,20211118,,HP,US,US,EFAVIRENZ,Cerebrovascular accident;Drug interaction,200837381,OT,,,,,,,,,200837381,1,Deep vein thrombosis
20089476,200894761,1,I,20030101,20211117,20211119,20211119,EXP,,DE-ABBVIE-21K-062-4165446-00,ABBVIE,,,,A,M,Y,,,20211119,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,200894761,OT,,,200894761,1,1997,,,,200894761,1,HIV infection
20090380,200903801,1,I,20160301,20211108,20211119,20211119,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-119682,BRISTOL MYERS SQUIBB,"Pohlman FW, McGee KS, McKellar MS. Case report: reversal of integrase inhibitor- and tenofovir alafenamide-related weight gain after switching back to efavirenz/emtricitabine/tenofovir DF. Open Forum Infectious Diseases. 2021;8(8):1-3",33,YR,,M,Y,,,20211119,,HP,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abnormal dreams;Diarrhoea;Sleep disorder;Weight decreased,,,,,200903801,1,201212,201603,,,200903801,1,HIV infection
20091164,200911641,1,I,,20211108,20211119,20211119,EXP,,TW-LUPIN PHARMACEUTICALS INC.-2021-22433,LUPIN,"Kao S-W, Liu Z-H, Wu T-S, Ku SW-W, Tsai C-L, Shie S-S, et al. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: An observational study in a tertiary hospital in Northern Taiwan, 2017-19. Journal of Antimicrobial Chemotherapy. 2021;76(3):722-728",,,,,Y,,,20211119,,HP,TW,TW,EFAVIRENZ,Drug resistance,200911641,OT,,,,,,,,,200911641,1,HIV infection
20095219,200952191,1,I,20080101,20211117,20211122,20211122,EXP,,DE-ABBVIE-21K-062-4165442-00,ABBVIE,,,,A,M,Y,,,20211122,,CN,DE,DE,EFAVIRENZ,Pathogen resistance,200952191,OT,,,200952191,1,1997,,,,200952191,1,HIV infection
20095242,200952421,1,I,20170101,20211112,20211122,20211122,EXP,,LV-VIIV HEALTHCARE LIMITED-LV2021EME234912,VIIV,,,,A,F,Y,,,20211122,,MD,LV,LV,EFAVIRENZ,Dizziness;Nausea;Pulmonary tuberculosis;Thrombocytopenia;Treatment noncompliance;Viral load abnormal,200952421,OT,,,200952421,1,2015,2017,4,MON,200952421,1,HIV infection CDC category A
20095259,200952591,1,I,20170101,20211112,20211122,20211122,EXP,,LV-GLAXOSMITHKLINE-LV2021EME234912,GLAXOSMITHKLINE,,,,A,F,Y,,,20211122,,MD,LV,LV,EFAVIRENZ,Dizziness;Nausea;Pulmonary tuberculosis;Thrombocytopenia;Treatment noncompliance;Viral load abnormal,200952591,OT,,,200952591,1,2015,2017,4,MON,200952591,1,HIV infection CDC category A
20099095,200990951,1,I,,20211116,20211122,20211122,EXP,,IN-MYLANLABS-2021M1086040,MYLAN,"Sirohi P, Dabas A, Nehara HR, Chhimpa AR, Barodia MK, Kumar R. Safety and efficacy of fixed drug combination tenofovir, lamivudine and efavirenz to prevent transmission of HIV. J-Clin-Diagnostic-Res 2021;15(7):OC01-OC05.",,,A,F,Y,,,20211122,,HP,IN,IN,EFAVIRENZ,Drug ineffective;Maternal exposure during pregnancy,200990951,OT,,,,,,,,,200990951,1,Prophylaxis against HIV infection
20103563,201035631,1,I,,20211113,20211123,20211123,EXP,,CA-TEVA-2021-CA-1979597,TEVA,,46,YR,A,M,Y,72,KG,20211123,,HP,CA,CA,EFAVIRENZ,Hepatotoxicity;Transaminases increased,201035631,OT,,,,,,,,,201035631,2,Pulmonary tuberculosis
20107504,201075042,2,F,,20211117,20211124,20211124,PER,,US-GILEAD-2021-0557833,GILEAD,,,,A,M,Y,,,20211124,,MD,US,US,EFAVIRENZ,Drug resistance,201075042,OT,,,,,,,,,201075042,1,HIV infection
20116120,201161201,1,I,,20211122,20211126,20211126,EXP,,CA-BAUSCH-BL-2021-038656,BAUSCH AND LOMB,,54,YR,,M,Y,,,20211126,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,201161201,OT,,,,,,,,,201161201,1,Bipolar disorder
20118031,201180311,1,I,,20211118,20211126,20211126,EXP,,CA-AstraZeneca-2021A820084,ASTRAZENECA,,54,YR,,M,Y,,,20211126,,MD,CA,,SUSTIVA,Depression;Drug interaction,201180311,OT,,,,,,,,,201180311,1,HIV infection
20119748,201197481,1,I,,20211115,20211126,20211126,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-121861,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211126,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities,201197481,OT,,,,,,,,,201197481,1,HIV infection
20123926,201239261,1,I,20210101,20211119,20211129,20211129,EXP,,GB-GILEAD-2021-0557694,GILEAD,,71,YR,E,M,Y,,,20211129,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,201239261,OT,,,201239261,1,20191114,201911,,,201239261,1,HIV infection
20124538,201245381,1,I,20080101,20211119,20211129,20211129,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125098,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20211129,,CN,DE,DE,EFAVIRENZ,Pathogen resistance,201245381,OT,,,201245381,1,1997,,,,201245381,1,HIV infection
20127740,201277401,1,I,20190820,20211118,20211129,20211129,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125151,BRISTOL MYERS SQUIBB,,34,YR,,F,Y,,,20211129,,MD,PT,PT,EFAVIRENZ,Blood cholesterol increased;Depression;Disseminated tuberculosis;High density lipoprotein decreased;Low density lipoprotein increased;Weight increased,201277401,OT,,,201277401,1,201606,202105,,,201277401,1,Product used for unknown indication
20130013,201300131,1,I,20030101,20211118,20211130,20211130,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-124807,BRISTOL MYERS SQUIBB,,,,A,M,Y,,,20211130,,CN,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,201300131,OT,,,201300131,1,1997,,,,201300131,1,HIV infection
20131250,201312501,1,I,20150601,20211119,20211130,20211130,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125171,BRISTOL MYERS SQUIBB,,41,YR,,M,Y,,,20211130,,MD,PT,PT,EFAVIRENZ,Agitation;Cytomegalovirus test positive;Dizziness;HIV infection;Irritability;Malaise;Multiple-drug resistance;Nightmare;Restlessness;Toxoplasma serology positive,201312501,OT,,,201312501,1,201505,,,,201312501,1,Product used for unknown indication
20133029,201330291,1,I,20190820,20211118,20211201,20211201,EXP,,PT-AUROBINDO-AUR-APL-2021-049207,AUROBINDO,,34,YR,,F,Y,,,20211201,,MD,PT,PT,EFAVIRENZ,Blood cholesterol increased;Depression;Disseminated tuberculosis;High density lipoprotein decreased;Low density lipoprotein increased;Weight increased,201330291,OT,,,201330291,1,201606,,,,201330291,1,Product used for unknown indication
20138555,201385551,1,I,20211029,20211123,20211202,20211202,EXP,,DE-GILEAD-2021-0558058,GILEAD,,51,YR,A,M,Y,57,KG,20211202,,MD,DE,DE,EFAVIRENZ\EMTRICITABINE\TENOFOVIR\TENOFOVIR DISOPROXIL FUMARATE,Coronary artery disease,201385551,OT,,,201385551,1,20150422,,,,201385551,1,Chronic hepatitis C
20140951,201409512,2,F,,20210609,20211202,20211214,EXP,,ES-MYLANLABS-2021M1089756,MYLAN,,,,A,,Y,,,20211214,,MD,ES,ES,EFAVIRENZ,Hypertension;Thrombosis,201409512,OT,,,,,,,,,201409512,1,Antiretroviral therapy
20141611,201416111,1,I,20170101,20211123,20211202,20211202,EXP,,LV-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-126077,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20211202,,CN,LV,LV,EFAVIRENZ,Dizziness;Nausea;Pulmonary tuberculosis;Thrombocytopenia;Treatment noncompliance;Viral load abnormal,201416111,OT,,,201416111,1,2015,2017,4,MON,201416111,1,HIV infection CDC category A
20141744,201417441,1,I,,20211124,20211202,20211202,EXP,,CA-TEVA-2021-CA-1983097,TEVA,,54,YR,A,M,Y,,,20211202,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,201417441,OT,,,,,,,,,201417441,1,HIV infection
20142455,201424552,2,F,,20211206,20211202,20211216,EXP,,US-TEVA-2021-US-1982405,TEVA,"Pohlman FW, Mcgee KS, Mckellar MS. Case Report: Reversal of Integrase Inhibitor- A nd Tenofovir Alafenamide-Related Weight Gain after Switching Back to Efavirenz/Emtricitabine/Tenofovir DF. Open-Forum-Infect-Dis 2021;8(8):ofab403.",33,YR,A,M,Y,66.7,KG,20211216,,HP,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abdominal pain;Diarrhoea;Sleep disorder;Weight decreased;Weight increased,201424552,OT,,,201424552,2,201603,,,,201424552,1,HIV infection
20143057,201430571,1,I,,20211123,20211202,20211202,EXP,,IR-STRIDES ARCOLAB LIMITED-2021SP030442,STRIDES,"Mardani M, Sharifi-Razavi A, Sheibani S, Baziboroun M.. Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report.. Curr-HIV-Res. 2021;19(4):377-382",61,YR,,M,Y,,,20211203,,HP,IR,IR,EFAVIRENZ,COVID-19,201430571,HO,,,201430571,1,2014,,,,201430571,1,HIV infection
20144068,201440681,1,I,20030101,20211122,20211203,20211203,EXP,,DE-ROCHE-2963337,ROCHE,,,,A,M,Y,,,20211203,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,201440681,OT,,,201440681,1,1997,,,,201440681,1,HIV infection
20145831,201458311,1,I,20080101,20211122,20211203,20211203,EXP,,DE-ROCHE-2963063,ROCHE,,,,A,M,Y,,,20211203,,MD,DE,DE,EFAVIRENZ,Pathogen resistance,201458311,OT,,,201458311,1,1997,,,,201458311,1,HIV infection
20148187,201481871,1,I,20150601,20211119,20211204,20211204,EXP,,PT-AUROBINDO-AUR-APL-2021-049938,AUROBINDO,,41,YR,,M,Y,,,20211204,,MD,PT,PT,EFAVIRENZ,Agitation;Cytomegalovirus test positive;Dizziness;HIV infection;Irritability;Malaise;Multiple-drug resistance;Nightmare;Restlessness;Toxoplasma serology positive,201481871,OT,,,201481871,1,201505,,,,201481871,1,Product used for unknown indication
20154505,201545051,1,I,,20211123,20211207,20211207,EXP,,IR-LUPIN PHARMACEUTICALS INC.-2021-23894,LUPIN,"Mardani M, Sharifi-Razavi A, Sheibani S, Baziboroun M. Outcome of a HIV positive patient infected with COVID-19 after an autologous bone marrow transplantation: A case report. Current HIV Research. 2021;19(4):377-382",61,YR,,M,Y,,,20211207,,HP,IR,IR,EFAVIRENZ,COVID-19;Off label use,201545051,HO,,,201545051,1,2014,,,,201545051,1,HIV infection
20155183,201551831,1,I,,20211130,20211207,20211207,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2021GSK249495,VIIV,"Meneghello BHS, Soares MMCN, Silva VCM, Lemos MF, Cervato MC, Filho JC et al.. Hepatitis B in the northwestern region of Sao Paulo State: Genotypes and resistance mutations. Revista do Instituto de Medicina Tropical de Sao Paulo. 2021;63",,,,,Y,,,20211207,,HP,BR,BR,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,201551831,OT,,,,,,,,,201551831,1,Hepatitis B
20155189,201551891,1,I,,20211130,20211207,20211207,EXP,,BR-GLAXOSMITHKLINE-BR2021GSK249495,GLAXOSMITHKLINE,"Meneghello BHS, Soares MMCN, Silva VCM, Lemos MF, Cervato MC, Filho JC et al.. Hepatitis B in the northwestern region of Sao Paulo State: Genotypes and resistance mutations. Revista do Instituto de Medicina Tropical de Sao Paulo. 2021;63",,,,,Y,,,20211207,,HP,BR,BR,EFAVIRENZ,Drug resistance;Pathogen resistance;Viral mutation identified,201551891,OT,,,,,,,,,201551891,1,Hepatitis B
20158798,201587981,1,I,20080101,20211130,20211208,20211208,EXP,,DE-009507513-2111DEU010374,MERCK,,,,A,M,Y,,,20211208,,MD,DE,DE,EFAVIRENZ,Pathogen resistance,201587981,OT,,,201587981,1,1997,,,,201587981,1,HIV infection
20160932,201609321,1,I,20030101,20211130,20211208,20211208,EXP,,DE-009507513-2111DEU010371,MERCK,,,,A,M,Y,,,20211208,,MD,DE,DE,EFAVIRENZ,Ophthalmic herpes zoster,201609321,OT,,,201609321,1,1997,,,,201609321,1,HIV infection
20164660,201646601,1,I,,20211206,20211209,20211209,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-114917,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211209,,HP,CA,CA,SUSTIVA,Death,201646601,DE,,,,,,,,,201646601,1,HIV infection
20167569,201675691,1,I,,20211206,20211209,20211209,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-133712,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211209,,HP,CA,CA,SUSTIVA,Death,201675691,DE,,,,,,,,,201675691,1,Product used for unknown indication
20168349,201683491,1,I,,20211201,20211210,20211210,EXP,,PT-AUROBINDO-AUR-APL-2021-050623,AUROBINDO,"Mouro M, Martins A, Soeiro C, Coutinho D, Velez J, Freitas F. et al.. Mono and dual therapies in human immunodeficiency virus infection.data from a district hospital.. unk. 2021;16 (2):56-65",,,A,,Y,,,20211210,,MD,PT,PT,EFAVIRENZ,Treatment failure,201683491,OT,,,,,,,,,201683491,1,HIV infection
20168471,201684711,1,I,,20211201,20211210,20211210,EXP,,PT-AUROBINDO-AUR-APL-2021-050618,AUROBINDO,"Mouro M, Martins A, Soeiro C, Coutinho D, Velez J, Freitas F et al. Mono and dual therapies in human immunodeficiency virus infection - data from a district hospital. 2021;16 (2):56-65",,,A,,Y,,,20211210,,MD,PT,PT,EFAVIRENZ,Genotype drug resistance test positive;Treatment failure,201684711,OT,,,,,,,,,201684711,1,HIV infection
20186076,201860761,1,I,,20211214,20211215,20211215,EXP,,CA-ABBVIE-21K-028-4199208-00,ABBVIE,,,,,M,Y,,,20211215,,CN,CA,CA,EFAVIRENZ,Depression;Drug interaction,201860761,OT,,,,,,,,,201860761,1,Product used for unknown indication
20199935,201999351,1,I,,20211202,20211217,20211217,EXP,,CA-ALVOGEN-2021-ALVOGEN-117943,ALVOGEN,,54,YR,,M,Y,,,20211217,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,201999351,OT,,,,,,,,,201999351,1,Bipolar disorder
20212821,202128211,1,I,20150601,20211216,20211221,20211221,EXP,,PT-MYLANLABS-2021M1093968,MYLAN,,41,YR,,M,Y,,,20211221,,MD,PT,PT,EFAVIRENZ,Agitation;Cytomegalovirus test positive;Dizziness;HIV infection;Irritability;Malaise;Multiple-drug resistance;Nightmare;Restlessness;Toxoplasma serology positive,202128211,OT,,,202128211,1,201505,,,,202128211,1,Product used for unknown indication
20216631,202166311,1,I,,20211215,20211222,20211222,EXP,,GB-MYLANLABS-2021M1094901,MYLAN,"Patel N, Childs K. The legacy of older ART agents: Multiple consequences of decades of NRTI therapy. HIV-Med 2021;22 (Suppl. 3):308 (plus poster) abstr. CCP1/16.",34,YR,,F,Y,,,20211222,,HP,GB,GB,EFAVIRENZ,Condition aggravated;Dysarthria;Dysphagia;Dysphonia;Hypophosphataemia;Lactic acidosis;Loss of personal independence in daily activities;Myopathy;Neuropathy peripheral;Neurotoxicity;Weight decreased,202166311,HO,,,,,,,,,202166311,1,HIV infection
20217005,202170051,1,I,20190820,20211216,20211222,20211222,EXP,,PT-MYLANLABS-2021M1093969,MYLAN,,34,YR,,F,Y,,,20211222,,MD,PT,PT,EFAVIRENZ,Blood cholesterol increased;Condition aggravated;Depression;Disseminated tuberculosis;High density lipoprotein decreased;Low density lipoprotein increased;Weight increased,202170051,OT,,,202170051,1,201606,,,,202170051,1,Product used for unknown indication
20217106,202171061,1,I,,20211215,20211222,20211222,EXP,,FR-MYLANLABS-2021M1095064,MYLAN,"Kherabi Y, De Castro N, Sellier P-O, Hamet G, Brun A, Digumber M, et al. Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection. A retrospective cohort study. HIV-Med 2021;22 (Suppl. 3):176 (plus poster) abstr. PE3/56.",,,,,Y,,,20211222,,HP,FR,FR,EFAVIRENZ,Pathogen resistance;Virologic failure,202171061,OT,,,,,,,,,202171061,1,Antiretroviral therapy
20217183,202171831,1,I,20170101,20211217,20211222,20211222,EXP,,LV-MYLANLABS-2021M1094387,MYLAN,,,,A,F,Y,,,20211222,,MD,LV,LV,EFAVIRENZ,Dizziness;Nausea;Pulmonary tuberculosis;Thrombocytopenia;Treatment noncompliance;Viral load abnormal,202171831,OT,,,202171831,1,2015,2017,4,MON,202171831,1,HIV infection CDC category A
20220742,202207421,1,I,,20211220,20211223,20211223,EXP,,CA-BAUSCH-BL-2021-042022,BAUSCH AND LOMB,,54,YR,,M,Y,,,20211223,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,202207421,OT,,,,,,,,,202207421,1,Bipolar disorder
20220747,202207471,1,I,,20211220,20211223,20211223,EXP,,CA-BAUSCH-BL-2021-042035,BAUSCH AND LOMB,,54,YR,,M,Y,,,20211223,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,202207471,OT,,,,,,,,,202207471,1,Bipolar disorder
20221478,202214781,1,I,,20211220,20211223,20211223,EXP,,CA-BAUSCH-BL-2021-042040,BAUSCH AND LOMB,,54,YR,,M,Y,,,20211223,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,202214781,OT,,,,,,,,,202214781,1,Bipolar disorder
20221479,202214791,1,I,,20211220,20211223,20211223,EXP,,CA-BAUSCH-BL-2021-042039,BAUSCH AND LOMB,,,,,M,Y,,,20211223,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,202214791,HO,,,,,,,,,202214791,1,Product used for unknown indication
20221480,202214801,1,I,,20211220,20211223,20211223,EXP,,CA-BAUSCH-BL-2021-042031,BAUSCH AND LOMB,,54,YR,,M,Y,,,20211223,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,202214801,DE,,,,,,,,,202214801,1,Bipolar disorder
20221481,202214811,1,I,,20211220,20211223,20211223,EXP,,CA-BAUSCH-BL-2021-042033,BAUSCH AND LOMB,,,,,M,Y,,,20211223,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,202214811,HO,,,,,,,,,202214811,1,Product used for unknown indication
20222129,202221291,1,I,,20211217,20211223,20211223,EXP,,CA-ROCHE-2984070,ROCHE,,,,,M,Y,,,20211223,,HP,CA,,SUSTIVA,Depression;Drug interaction,202221291,DE,,,,,,,,,202221291,1,Product used for unknown indication
20222445,202224451,1,I,,20211215,20211223,20211223,EXP,,CA-AstraZeneca-2021A877401,ASTRAZENECA,,54,YR,,M,Y,,,20211223,,MD,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,202224451,OT,,,,,,,,,202224451,1,Bipolar disorder
20223103,202231031,1,I,,20211215,20211223,20211223,EXP,,CA-AstraZeneca-2021A877500,ASTRAZENECA,,54,YR,,M,Y,,,20211223,,MD,CA,,SUSTIVA,Depression;Drug interaction,202231031,OT,,,,,,,,,202231031,1,Product used for unknown indication
20224115,202241151,1,I,,20211217,20211223,20211223,EXP,,CA-ROCHE-2983728,ROCHE,,,,,M,Y,,,20211223,,HP,CA,,SUSTIVA,Depression;Drug interaction,202241151,DE,,,,,,,,,202241151,1,Product used for unknown indication
20232432,202324321,1,I,,20211220,20211227,20211227,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK261922,GLAXOSMITHKLINE,,,,,M,Y,,,20211227,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,202324321,HO,,,,,,,,,202324321,1,Product used for unknown indication
20232560,202325601,1,I,,20211220,20211227,20211227,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK261922,VIIV,,,,,M,Y,,,20211227,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,202325601,HO,,,,,,,,,202325601,1,Product used for unknown indication
20233323,202333231,1,I,,20211220,20211227,20211227,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK261757,VIIV,,54,YR,,M,Y,,,20211227,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,202333231,OT,,,,,,,,,202333231,1,Bipolar disorder
20233408,202334081,1,I,,20211220,20211227,20211227,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK261757,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20211227,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,202334081,OT,,,,,,,,,202334081,1,Bipolar disorder
20245780,202457801,1,I,,20211215,20211229,20211229,EXP,,GB-HORMOSAN PHARMA GMBH-2021-25819,LUPIN,"Patel N, Childs K. The legacy of older ART agents: Multiple consequences of decades of NRTI therapy. HIV Medicine. 2021;22(3):308",52,YR,,F,Y,,,20211229,,HP,GB,GB,EFAVIRENZ,Dysarthria;Dysphagia;Dysphonia;Hypophosphataemia;Lactic acidosis;Loss of personal independence in daily activities;Myopathy;Neuropathy peripheral;Neurotoxicity;Weight decreased,202457801,HO,,,,,,,,,202457801,1,HIV infection
20247277,202472771,1,I,,20211222,20211229,20211229,EXP,,PT-MYLANLABS-2021M1095986,MYLAN,"Mouro M, Martins A, Soeiro C, Coutinho D, Velez J, Freitas F et al.. Mono and dual therapies in human immunodeficiency virus infection - data from a district hospital.. 2021;16(2):56-65",,,A,,Y,,,20211229,,MD,PT,PT,EFAVIRENZ,Genotype drug resistance test positive;Treatment failure,202472771,OT,,,,,,,,,202472771,1,HIV infection
20248402,202484021,1,I,,20211219,20211229,20211229,EXP,,CA-TEVA-2021-CA-1992471,TEVA,,54,YR,A,M,Y,,,20211229,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,202484021,OT,,,,,,,,,202484021,1,HIV infection
20248728,202487281,1,I,,20211219,20211229,20211229,EXP,,CA-TEVA-2021-CA-1992487,TEVA,,54,YR,A,M,Y,,,20211229,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,202487281,OT,,,,,,,,,202487281,1,HIV infection
6870587,68705875,5,F,20060602,20211012,20081231,20211025,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14457303,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20211025,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,68705875,HO,,,68705875,2,20060602,20070522,355,DAY,68705875,1,HIV infection
6870591,68705914,4,F,,20211012,20081231,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14455729,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20211020,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use;Prescribed overdose,68705914,DE,,,68705914,1,2004,,,,68705914,1,HIV infection
7686793,768679325,25,F,20070423,20211220,20101130,20211231,EXP,,JP-JNJFOC-20101108379,JOHNSON AND JOHNSON,,28,YR,A,M,Y,,,20211231,,MD,JP,JP,EFAVIRENZ,Abdominal distension;Atrioventricular block second degree;Blood triglycerides increased;Bradycardia;Campylobacter gastroenteritis;Dyslipidaemia;Gastrointestinal haemorrhage;Haemoglobin decreased;Haemorrhoids;Hepatic function abnormal;Herpes zoster;Liver function test abnormal;Liver function test increased;Malaise;Oropharyngeal discomfort;Tachycardia paroxysmal,768679325,HO,,,768679325,1,20060905,20181001,12,YR,768679325,1,HIV infection
